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ABSTRACT  
 
Background: Deficits in cognition and social and role functioning are characteristics of 
schizophrenia and have been found to impair every day functioning. A robust body of 
evidence has shown that such cognitive and functional deficits have been observed in 
individuals who are deemed to be at Clinical High-Risk (CHR) for developing psychosis. 
More severe cognitive dysfunction is associated with poorer functional outcomes in both 
schizophrenia and in CHR. Identifying the pattern and severity of cognitive and functional 
deficits for those who are CHR could identify important treatment targets for early 
intervention. 
Aims: To identify differences in cognitive, social cognitive and psychosocial functioning in 
those who are at CHR of developing psychosis relative to controls. Additionally, we intent 
to identify to what extent does neuro- and social cognition explain poor functioning in the 
CHR population. 
Methods: Baseline neuro- and social cognition was assessed along with GAF, social and 
role functioning measures in a sample of 110 CHR-participants and 46 healthy controls. 
Demographic and clinical characteristic data were also collected and analysed. 
Results: CHR-participants showed deficits in the areas of motor speed, processing speed, 
working memory, global cognitive score and were significantly slower at recognising facial 
affect relative to controls. CHR-participants had significantly poorer social and role 
functioning and lower GAF scores. Regression analysis found response time for facial affect 
to be related to GAF and social functioning as baseline whilst global cognitive score was 
associated with role functioning. Exploratory analysis found response times for the 
recognition of sad faces to be associated with GAF whilst response times for the recognition 
of fearful face were associated with both social and role functioning at baseline.    
Conclusions: Neuro- and social cognitive impairment, particularly in motor speed, 
processing speed, working memory and response times for emotion recognition has been 
observed in CHR-individuals. Response times for recognising emotion and global cognition 
have been associated with poor functioning at baseline. These findings highlight putative 
treatment targets for early intervention.  
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Definitions/abbreviations 
 
ANOVA: Analysis if variance  
 
APS: Attenuated psychosis syndrome  
 
ARMS: At risk mental state 
 
BACS: Brief Assessment of Cognition in Schizophrenia 
 
BLIP: Brief limited intermittent psychosis 
 
BS: Basic symptoms 
 
CAARMS: Comprehensive Assessment of At-Risk Mental States 
 
CBT: Cognitive behavioural therapy 
 
CHR: Clinical high-risk 
 
CNS:  Central nervous system 
 
CNV: Copy number variant 
 
COMT: Catechol-O-methyl transferase 
 
CPT: Continuous performance task 
 
CT: Computer tomography 
 
DISC1: Disrupted-in-schizophrenia 1  
 
DSM:  
 
Diagnostic and Statistical Manual of Mental Disorders 
DTNBP1: Dysbindin 
 
FEP:  First episode of psychosis 
 
GABA: γ-Amino Butyric Acid 
 
GAF: Global assessment of functioning  
 
GF Role: Global functioning role scale  
 
GF Social: Global functioning social scale  
 
GRD: Genetic risk and deterioration syndrome 
 
GRM3: Metabotropic glutamate receptor 3  
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Gln: Glutamine  
 
Glu: Glutamate 
 
GWAS: Genome-wide association studies 
 
HR: High risk 
 
LNB: Letter-number-back task  
 
MRI: Magnetic resonance imaging 
 
NAA: N -Acetylaspartic acid 
 
NAPLS: North American prodrome longitudinal study 
 
NCP: Non-clinical psychosis 
 
NMDA: 
 
N -methyl- d -aspartate 
NRG1: Neuregulin 1  
 
RGS4: 
 
Regulator of G-protein signaling 4  
 
PAS: Premorbid adjustment scale 
 
PCA:  Perceptual-cognitive anomalies 
 
PennCNB: University of Pennsylvania computerized neuropsychological testing 
battery 
 
PQ: Prodromal questionnaire 
 
RT: Reaction time  
 
SIPS: Structured interview for prodromal symptoms 
 
SOPS: Scale of prodromal symptoms  
 
SPI-A: Schizophrenia proneness instrument-adult version 
 
SPI-CY: Schizophrenia proneness instrument-child and youth version 
 
UHR: Ultra-high-risk 
 
UPS: Unspecified prodromal symptoms  
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1. INTRODUCTION 
 
Psychiatric disorders are major public health concerns with schizophrenia and 
schizoaffective disorder combined being the 5th leading cause of disability worldwide 
(WHO). Schizophrenia can result in a severe and chronic psychiatric disorder and is 
characterised by abnormalities in the domains of positive symptoms (delusions, 
hallucinations), negative symptoms (flattened affect, social withdrawal), disorganised 
thinking and cognition. Schizophrenia has a prevalence rate of 1.1% worldwide (National 
Institute of Mental Health, 2011). Due to the debilitating positive and negative symptoms of 
schizophrenia, in chronic cases an individual’s functional capacity can be significantly 
impaired, resulting in long term unemployment coupled with long term medical and social 
care needs at enormous cost to the economy (Knapp, Mangalore & Simon, 2004).  
Cognitive deficits are not included in the diagnostic criteria. However, they have consistently 
been found to be a core feature of the disorder (Rajji, Miranda & Mulsant, 2014) and are 
highly associated with functional disability (Rajji, Miranda & Mulsant, 2014). Over the last 
few decades, research into the prevalence, course and profile of cognitive dysfunctions has 
extended into groups of individuals who are considered to be at-risk of developing 
schizophrenia and related psychotic disorders.  
This thesis will firstly review existing literature on the history and aetiology of schizophrenia 
before presenting a novel research study investigating the relationship between attenuated 
psychotic experiences, cognitive deficits and current psychosocial functioning.       
 
1.1 History of the concept of Schizophrenia 
 
What is now conceptualised as schizophrenia has existed historically under various names. 
Emile Kraepelin (Hoeing, 1983) combined the previously separate constructs of dementia 
paranoids, hebephrenia and catatonia into a single definition of ‘dementia praecox’ 
(Bruijnzeel, & Tandon, 2011). An important aspect of Kraepelin’s work was the belief that 
there existed two distinct patterns of illness course around which many of the different 
conditions could be grouped: 1) dementia praecox and 2) manic depressive insanity (today 
known as bipolar disorder).  
Kraepelin identified dementia praecox on the basis of its onset in adolescence, its 
deteriorating course and its outcome of demence or “mental dullness” (Hoeing, 1983). In 
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contrast, Kraepelin argued that manic depressive insanity was distinct from dementia 
praecox based on its fluctuating presentation and better outcome (Bruijnzeel, & Tandon, 
2011). A key contribution to Kraepelin’s understanding of dementia praecox came from his 
meticulous follow up of individual cases. Having been unsuccessful at specifying disorders 
based on purely anatomical, aetiological or psychopathological criteria, he therefore 
promoted his belief in the interdependence of disciplines, later adding course and treatment 
response (Hoeing, 1983).  
Eugen Bleuler (1857-1939) coined the phrase schizophrenia. Bleuler and his apprentice 
Jung, who had both been influenced by Freud’s work regarding the neuroses, aimed to 
introduce the ‘psyche’ to the concept of dementia praecox. Bleulers’ publication ‘Dementia 
praecox or the Group of Schizophrenias’ (1911) forwarded the name schizophrenia to 
highlight the ‘split of several psychic functions’ as one of the most important characteristics. 
He added the concept of ‘loosening of associations’ and described four ‘basic symptoms’ of 
schizophrenia (the 4 As):  
 Associational disturbances (tangential or loose-thought processes) 
 Affective incongruenty (flat or inappropriate affect) 
 Autism (withdrawal from reality to fantasy) 
 Ambivalence (mental and / or physical vacillation or indecisiveness) 
Experiences of hallucinations and delusions (which occur in other disorders as well as 
schizophrenia) were regarded as “accessory symptoms” which he believed were a result of 
adaptive and defensive reactions. (Häfner, 2014). Although Bleulers use of the terms 
‘loosening of associations’ and ‘splitting’ have been interpreted over the years as a 
separation of thought and affect, many argue that this in fact refers to dissociation. 
Importantly Bleuler assumed continuity between normality and psychosis forming a basis 
for the dimensional model of schizophrenia, as opposed to Kraepelins categorical model, an 
argument with is still heavily debated today. 
Schneider aimed to further define schizophrenia by differentiating between symptoms of 
first and second rank in his book ‘Clinical Psychopathology’ (1959). Schneider regarded the 
presence of one or more of the first rank symptoms he had identified as sufficient for a 
diagnosis of schizophrenia (Warner & Girolamo, 1995). Similar to Kraepelin, Schneider 
considered symptoms to be early signs of an undetected somatic process. He adopted the use 
of the term “endogeneity” as a term used to mark the category of disorders of unknown 
biological origin as represented by schizophrenia (Häfner, 2014).  
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Although the terminology of the first rank symptoms are still widely used today, their 
diagnostic power has been heavily criticised. First rank symptoms are present in a range of 
psychiatric disorders and can be experienced in a similar way to those with a diagnosis of 
schizophrenia in terms of phenomenology, emotional impact and persistence over time 
(Renard, Huntjens, Lysaker, Moskowitz, Aleman, & Pijnenborg, 2017; Schroeder, Fisher & 
Schäfer, 2013).  In the second half of the 20th century the emergence of neuroleptic drugs 
brought forward what was to be the most enduring biological hypotheses of schizophrenia – 
the dopamine hypothesis. This brought about a focus on brain chemistry and models of 
schizophrenia lost any focus on psychological and environmental influences. Schizophrenia 
was now known as a dopamine disorder after the psychosis inducing effects of dopamine 
releasing drugs such as amphetamines coupled with the efficacy of antipsychotic drugs 
known to block the dopamine D2 receptor (Carlson, 1988). This neurochemical 
understanding of schizophrenia transformed treatment of schizophrenia though anti-
psychotic medications which allowed people to be treated in the community and out of 
hospital and even, in some cases, showing remission of some of the major symptoms of 
schizophrenia (Insel, 2010). However, these medications had unpleasant side effects, known 
as extrapyramidal symptoms, which include tremors and rigidity. A new wave of atypical 
anti-psychotics, which were hailed to be of increased efficaciousness, were found to reduce 
these extrapyramidal side effects but unfortunately are not significantly more efficacious 
than the original dopamine D2 receptor antagonists (Lieberman, Stroup, McEvoy, Swartz, 
Rosenheck & Perkins, 2005). Although these drugs have reduced the experiences of positive 
symptoms to some extent, they have been ineffective at improving the functional outcome 
of individuals with a diagnosis of schizophrenia. One explanation for this is that poor 
functional outcome in schizophrenia is largely due to the cognitive deficits, for example 
attention and working memory, which these drugs do not treat (Insel, 2010). Therefore, 
understanding and treating cognitive deficits, as well as positive symptoms, may be a more 
efficacious treatment target for schizophrenia.         
Another well-accepted model of schizophrenia, and indeed general psychopathology, is the 
stress-vulnerability hypothesis (Nuechterlein & Dawson, 1984; Zubin & Spring, 1977; 
Katschnig, 1990). According to this model, symptoms of psychosis appear once a 
combination of stressors reach the individual’s vulnerability threshold. However, as this 
concept is interactional it is inherently difficult to investigate (Myin-Germeys, van Os, 
Schwartz, Stone, & Delespaul, 2001). Support has come from reports of individuals with a 
diagnosis of schizophrenia as being more sensitive to the stress of daily life events relative 
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to their non-psychiatric counterparts (Bebbington, Wilkins, Jones, Foerster, Murray, Toone, 
& Lewis, 1993; Lukoff, Ventura & Nuechterlein, 1984).    
 
1.2 Prevalence, Development and Course  
 
The incidence of Schizophrenia is approximately 15.2/100,000 persons with the central 80% 
of estimates varying over a fivefold range (7.7–43.0/100,000). Variation of frequency has 
been found based on urbanicity, economic status, and latitude (McGrath, Saha, Chant & 
Welham, 2008). Although incidence has been found not to significantly differ between males 
and females (McGrath, Saha, Chant & Welham, 2008), gender differences have been found 
in relation to symptomology. Negative symptoms appear to be more pronounced in males 
and are associated with poorer outcomes. Additionally, diagnosis in males is associated with 
worse premorbid adjustment, more prominent cognitive dysfunction, and lower educational 
attainment (DSM IV). Cases which include more affective symptoms and brief 
presentations, which are often associated with better outcomes, are of equal prevalence in 
both genders. Typically, symptoms of schizophrenia emerge between late teens and mid-
30s. Onset pre-adolescence can occur but is rare. Most commonly, the peek onset age for 
males is mid-20s and late-20s for females (DSM IV).    
 
1.3 Symptoms and Features of Schizophrenia 
 
The key features of schizophrenia spectrum disorders include delusions, hallucinations, 
disorganised thinking, grossly disorganised motor behaviour (including catatonia) and 
negative symptoms. Although not typically seen as criteria for a diagnosis, schizophrenia is 
associated with impairments in cognition, social and role functioning (Carrión, Goldberg, 
McLaughlin, Auther, Correll & Cornblatt, 2011). This has been a key focus of research and 
a large body of evidence has provided an overall profile of domains of dysfunction (e.g. 
cognitive, emotional and behavioural). It is important to note that schizophrenia is a 
heterogeneous clinical syndrome thus individuals will vary substantially on the presentation 
of clinical features of the disorder. For example, grandiosity is a common feature of 
schizophrenia but not everyone will experience this. Similarly, many individuals experience 
hallucinations but not all. Additionally, no single symptom of the disorder is pathognomonic 
of schizophrenia. Schizophrenia is diagnostically recognised by a cluster of the symptoms 
13 
 
associated with the disorder. This is often accompanied with deficits in social and role 
functioning (DSM 5).  
 
1.4 Risk Factors 
 
For over 40 years, researchers have aimed to identify genetic and environmental 
determinants of schizophrenia. A consensus of this research is that schizophrenia is a 
complex disorder that comprises interacting genetic and environmental risk factors. A wide 
range of risk factors for developing schizophrenia have been identified. 
 
1.4.1 Genetic risk 
 
Schizophrenia is seen as a highly heritable disorder (Gottesman & Shields, 1972) with a 
heritability rate of 64-81% (Giusti-Rodríguez & Sullivan, 2013). There have been many 
approaches to the study of genetics in schizophrenia. Converging data have suggested a role 
for both rare and common variants in elevating the risk of schizophrenia. Importantly, there 
is no evidence of Mendelian forms of schizophrenia (rare mutations with deterministic 
effects) (Giusti-Rodríguez & Sullivan, 2013). Studies of candidate genes have highlighted 
various disease predisposing DNA sequence variants in disrupted-in-schizophrenia 1 
(DISC1), neuregulin 1 (NRG1), catechol-O-methyl transferase (COMT), regulator of G-
protein signaling 4 (RGS4), metabotropic glutamate receptor 3 (GRM3), dysbindin 
(DTNBP1), G72, and other sequences (Harrison and Weinberger, 2005), however these 
findings have been difficult to replicate (Schmidt & Mirnics, 2015). There is evidence for 
rare copy number variants (CNVs) which may have large effect sizes which play a role in 
the predisposition of schizophrenia. These result from deletions or duplications of relatively 
large genomic regions. The CNVs implicated in schizophrenia span multiple genes and can 
increase the risk of developing schizophrenia or protect against it (Grozeva, Kirov, Ivanov, 
Jones, Jones, Green, et al., 2010). This is evidenced by findings of 22q11 hemideletion being 
associated with schizophrenia (Karayiorgou, Simon & Gogos, 2010), whilst 22q11 
duplication has been suggested to protect against it (Rees, Kirov, Sanders, Walters, 
Chambert, Shi, et al., 2014). This suggests that expression levels, or ‘dose’ of specific genes 
are essential to typical and pathological brain development (Schmidt & Mirnics, 2015).  
More recently, given the expanding patient cohorts and increasingly sophisticated 
methodological approaches, genome-wide association studies (GWAS) can analyse DNA 
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from tens of thousands of patients with a diagnosis of schizophrenia. This method has so far 
identified between ‘one and several thousands of common alleles of very small effect’ which 
are associated with schizophrenia (Schmidt & Mirnics, 2015; McAllister, 2014; Ripke, 
O’Dushlaine, Chambert, Moran, Kähler, Akterin, et al., 2013). Calcium signaling has 
appeared as a potentially important factor in the etiology of schizophrenia (Giusti-Rodríguez 
& Sullivan, 2013) as these are essential for learning, memory and synaptic plasticity 
(Moosmang, Haider, Klugbauer, Adelsberger, Langwieser, Müller, et al., 2005). The 
MicroRNA 137 has also appeared as a potentially relevant risk factor for the development 
of schizophrenia. (Ripke, O’Dushlaine, Chambert, Moran, Kähler, Akterin, et al., 2013). In 
previous research miR-137 has been found to be important for neurodevelopment, adult 
neural stem cell proliferation and differentiation and dendritic arborization (Giusti-
Rodríguez & Sullivan, 2013).  
As schizophrenia risk is known to result from both genetic and environmental factors, 
researchers are now attempting to investigate both these factors together by looking at how 
specific environmental and genetic risk factors act to predispose or protect individuals from 
developing schizophrenia, whether the effects are additive, or there are gene x environment 
interactions (Giusti-Rodríguez & Sullivan, 2013). 
 
1.4.2 Environmental factors   
 
1.4.2.1 Pre- and perinatal risk 
 
Infection: Studies are continuing to associate prenatal infection with the development of 
schizophrenia (Brown & Derkits, 2009). Exposure to rubella, toxoplasma and herpes 
simplex virus type 2 causes a range of developmental disorders, including learning 
disabilities, mental retardation and sensorineural dysfunction (Remington, Klein, Wilson & 
Baker, 2005). Toxoplasma gondii infection has most consistently been associated with 
schizophrenia. Studies have found that mothers with higher immunoglobulin G level had a 
relative risk of 1.73 (Pedersen, Stevens, Pedersen, Norgaard-Pedersen & Mortensen, 2011) 
and new-borns found to have T. gondii immunoglobulin antibodies were also associated with 
elevated levels of schizophrenia (Mortensen, Nørgaard-Pedersen, Waltoft, Sørensen, 
Hougaard, Torrey, & Yolken, 2007). However, the underlying mechanisms relating to risk 
factors of prenatal infection remain unclear.  
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Nutrition: A few studies have found elevated risk of schizophrenia in relation to famine. It 
was found that individuals who were in utero during a time of famine showed an increased 
risk of schizophrenia, depression and brain abnormalities. The association with increased 
risk of schizophrenia has been replicated in two Chinese studies which showed a two-fold 
increase in risk in relation to sustained famine (St Clair, Xu, Wang, Yu, Fang, Zhang, et al., 
2005; Xu, Sun, Liu, Feng, Yu, Yang et al., 2009). Again, however, there is a lack of 
specificity in the association of famine pre- and perinatal famine and schizophrenia as it is 
also associated with mood disorders and antisocial behaviour, as well as a number of 
physiological abnormalities (Lumey, Stein, & Susser, 2011). 
Low birth weight: Epidemiological studies have consistently found preterm and low birth 
weight (<37 weeks, <2055 g) to be a general risk factor for psychiatric disorders, including 
schizophrenia (Rapport et al., 2012). Such studies have identified a broad increase in 
disorders including attention deficit hyperactivity disorder, autism spectrum disorder and 
intellectual disability and are often found to be comorbid with cognitive impairment 
(Rapport et al., 2012).  
 
1.4.2.2 Premorbid risk 
 
Urban environment: It is increasingly being argued that schizophrenia and psychotic 
disorders can be understood as disorders of adaption to social context. A consistent 
association between urban living and schizophrenia has been found (van Os, Kenis, & 
Rutten, 2010). This has been shown to exist in a dose response relationship (March, Hatch, 
Morgan, Kirkbride, Bresnahan, Fearon, & Susser, 2008). There are a large number of 
possible confounds that can occur, for example, higher rates of schizophrenia seen in urban 
environments could be secondary to higher rates of drug use or ethnic minority status. For 
this reason, large studies have controlled for a number of possible confounders, including 
indexing for genetic risk to exclude environmental and genetic confounders (Krabbendam, 
& Van Os, 2005; Kelly, O'Callaghan, Waddington, Feeney, Browne, Scully, et al., 2010). 
Additionally, longitudinal studies have shown that changing environmental exposure and 
moving from urban to rural environments in childhood is associated with a corresponding 
decrease in the risk for psychotic outcomes (Pedersen & Mortensen, 2001).  
Minority group status: Meta-analyses have consistently found an association between 
schizophrenia and minority group status across a wide range of settings and is thought to be 
relevant to both first and second-degree migrants (Cantor-Graae & Selten, 2005; Bourque, 
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van der Ven & Malla, 2011) and also for minority groups without recent migration 
(Bresnahan, Begg, Brown, Schaefer, Sohler, Insel et al., 2007). This indicates that the 
association with schizophrenia risk is not with migrations itself or pre-migration factors (van 
Os, Kenis, & Rutten, 2010). Moreover, studies have shown that the effect of minority status 
is dependent on other factors, such as the density of the population, for example, the higher 
the population of the individuals own ethnic group in that area, the lower the risk of 
schizophrenia (Veling, Susser, Van Os, Mackenbach, Selten, & Hoek, 2008). This suggests 
that migration and minority status constitute a risk factor in the context of social 
marginalisation and exclusion (Selten, & Cantor-Graae, 2005) and may be mediated by 
factors such as social diversity and discrimination (Morgan, Charalambides, Hutchinson & 
Murray, 2010). 
Childhood trauma: Over the past decade, the relationship between childhood trauma and 
psychotic disorders has been an active area of research. These studies consistently find high 
rates of childhood trauma in individuals with psychotic disorders, particularly childhood 
sexual abuse and physical abuse. A review of such studies recently found that 42% of female 
patients reported childhood sexual abuse and 35% reported childhood physical abuse 
(Morgan & Fisher, 2007). In males, these numbers were 28% and 38% respectively and at 
least one form of abuse was found in 50% of patients irrespective of gender (Morgan & 
Fisher, 2007). Childhood abuse is increasingly seen as a causal factor for schizophrenia. 
More specifically, childhood sexual abuse is associated with symptoms such as 
hallucinations, particularly auditory hallucinations in the context of comments and command 
hallucinations (Read, Os, Morrison, & Ross, 2005).  
Cannabis use: There is now robust evidence highlighting the association between cannabis 
and schizophrenia (Hall & Degenhardt, 2009; Moore, Zammit, Lingford-Hughes, Barnes, 
Jones, Burke & Lewis, 2007). There is an over representation of heavy cannabis use in new 
cases of schizophrenia (Barbee, Clark, Crapanzano, Heintz & Kehoe, 1989; Wheatley, 
1998). This sparked debate as to whether cannabis use is a contributory factor in developing 
psychosis or whether this over representation reflects a trend for self-medication for early 
symptoms of schizophrenia (Hall & Degenhardt, 2008; Ferdinand, Sondeijker, Van Der 
Ende, Selten, Huizink & Verhulst, 2005). Cannabis has been found to cause transient 
psychotic symptoms and impaired cognition in healthy controls (Morrison, Zois, McKeown, 
Lee, Holt, Powell et al, 2009) and that this response is exaggerated in individual who are at 
genetic risk for psychosis (D’Souza, Abi-Saab, Madonick, Forselius-Bielen, Doersch, 
Braley et al, 2005).  
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1.5 Cognition in Schizophrenia 
 
Cognitive deficits are a prominent feature of schizophrenia and can be found in almost all 
patients with a diagnosis of schizophrenia (Keefe & Harvey, 2012). Individuals have been 
found to be moderately to severely impaired over several cognitive domains with the average 
cognitive impairment reaching 2 standard deviations below that of non-psychiatric controls 
(Harvey & Keefe, 1997; Heinrichs & Zakzanis, 1998; Keefe, Fox, Harvey, Cucchiaro, Siu 
& Loebel, 2011).  
Studies have found that 27% of people with a diagnosis of schizophrenia do not show 
cognitive deficits (Palmer, Heaton, Paulsen, Kuck, Braff, Harris, et al., 1997). This sub-
group of patients tend to have the highest levels of premorbid functioning (Kremen, 
Seidman, Faraone, Toomey, & Tsuang, 2000), however, they show cognitive functioning 
that is significantly lower than what would be expected based on their premorbid functioning 
and parental education levels (Keefe & Harvey, 2012). In addition, up 98% of individuals 
with a diagnosis of schizophrenia perform more poorly than what would be expected based 
on parental education levels (Keefe, Eesley & Poe, 2005). Studies of monozygotic twins 
discordant for schizophrenia have found that almost all affected twins perform more poorly 
than their non-affected twin (Goldberg, Ragland, Torrey, Gold, Bigelow & Weinberger, 
1990).    
Neurocognitive assessments often assess more than one domain of cognitive functioning and 
many of these tests do not fit neatly into one single domain which has resulted in differences 
in the literature regarding the profile of neurocognitive impairment in schizophrenia (Keefe 
& Harvey, 2012). However, it is generally considered that the most important neurocognitive 
deficits in schizophrenia are in the domains of working memory, verbal learning and 
memory, motor ability, attention/vigilance, reasoning and problem solving, processing speed 
and social cognition (Dickinson, Ramsey & Gold 2007; Green, Nuechterlein, Gold, Barch, 
Cohen, Essock, et al., 2004). 
Working memory: Working memory has been described as a core component of 
neurocognitive impairment in schizophrenia (Brekke, Long, Nesbitt, & Sobel, 1997; 
Goldman-Rakic, 1994; Keefe, 2000). Deficits in working memory have been found to be 
associated with functional outcomes such as employment status (Lysaker & Bell, 1995) and 
job tenure (Gold, Goldberg, McNary, Dixon & Lehman, 2002). Deficits in working memory 
has also been found to be strongly associated with other domains which are impaired in 
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schizophrenia such as attention, planning, memory (Silver, Feldman, Bilker & Gur, 2003) 
and intelligence (Keefe, 2000). Additionally, neuroanatomical research has found that neural 
circuitry, including prefrontal cortical regions, mediates particular aspects of working 
memory functioning (Baddeley, 1992; Callicott, Mattay, Bertolino, Finn, Coppola, Frank, et 
al., 1999) and that this circuitry may be impaired in individuals with schizophrenia 
(Baddeley, 1992; Goldman-Rakic, 1987).     
Verbal learning and memory: This includes abilities in learning new information, retaining 
that information over time and recognising previously seen stimuli. Generally, individuals 
with a diagnosis of schizophrenia demonstrate larger deficits in learning than in retention 
(Keefe & Harvey, 2012). The tasks used to assess learning often involve the participant 
learning lists of word or written passages. There is substantial literature which highlights 
severe verbal memory impairments in schizophrenia (Aleman, Hijman, de Haan & Kahn, 
1999). There is a strong connection between verbal learning and social functioning in 
individuals with a diagnosis of schizophrenia both in real work functioning (Green, 1996) 
and in performances on social competency tasks (McClure, Bowie, Patterson, Heaton, 
Weaver, Anderson & Harvey, 2007).  
Motor ability: Schizophrenia is associated with deficits in pure motor speed (Hoff, Harris, 
Faustman, Beal, DeVilliers, Mone, et al., 1996). Motor procedural learning has been found 
to be intact (Schmand, Brand & Kuipers, 1992), however, bilateral and unilateral motor 
performance is impaired (Heinrichs & Zakzanis, 1998). Moreover, youths who later develop 
a schizophrenia spectrum disorder have been reported to show poorer motor function in 
childhood (Dickson, Laurens, Cullen & Hodgins, 2012).  
Attention (and vigilance): Vigilance refers to the ability to maintain attention over time. 
This is important for following social conversations, following instructions, and even simple 
activities such as reading and watching TV (Keefe & Harvey, 2012). Deficits in vigilance 
are associated with various outcomes including skills acquisition, social deficits and 
community functioning (Green, 1996; Green, Kern, Braff & Mintz, 2000). 
Reasoning and problem solving: Again, there are many differing measures for reasoning 
and problem solving. Previous studies have found that individuals with a diagnosis of 
schizophrenia had very poor performance on reasoning and problem-solving tasks and there 
was found to be reduced activity in the dorsolateral prefrontal cortex (Weinberger, 1987; 
Goldberg et al, 1987).  This led to a drive in research towards a hypothesis of frontal hypo-
activation in schizophrenia. However, many of these studies used the Wisconsin Card 
Sorting Test (WCST) as a measure of reason and problem solving which actually reflect a 
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number of cognitive functions and cannot be considered to be a pure measure of executive 
functions (Keefe, 1995).      
Processing speed: Neurocognitive tasks can require participants to rapidly process 
information and performance can be compromised by deficits in processing speed. A 
common task for this is a coding task which has been found to demonstrate the most severe 
impairments in schizophrenia (Dickenson, Ramsey & Gold, 2007). Impairments in 
processing speed have been linked to a variety of clinically important features of 
schizophrenia such as daily life activities (Evans, Heaton, Paulsen, Palmer, Patterson & 
Jeste, 2003), job tenure (Gold, Goldberg, McNary, Dixon & Lehman, 2002) and independent 
living status (Brekke, Long, Nesbitt & Sobel, 1997). 
Social cognition: Theory of mind, emotion perception and recognition has been a key focus 
in social cognition research in schizophrenia (Keefe & Harvey, 2012). Theory of mind refers 
to the ability to infer another’s intentions and/or to represent the mental states of others. 
Individuals with a diagnosis of schizophrenia have consistently been found to perform 
poorly on measures of theory of mind (Tan, Choo, Fones, & Chee, 2005; Corcoran, Mercer, 
& Frith, 1995). Facial emotion recognition is a well document deficit in schizophrenia and 
first episode psychosis (FEP) (Edwards, Jackson & Pattison, 2002; Hoekert, Kahn, 
Pijnenborg & Aleman, 2007; Kohler, Walker, Martin, Healey & Moberg, 2010). This is an 
important part of social cognition and is essential for guiding social interactions and 
therefore social functioning. Impairments in facial emotion recognition may therefore be 
implicit in deficits in social functioning which is a key feature of schizophrenia (Couture, 
Penn & Roberts, 2006; Pinkham, Penn, Perkins & Lieberman, 2003) and is also present in 
CHR samples (Addington, Penn, Woods, Addington & Perkins, 2008; Phillips & Seidman, 
2008).   
Edwards et al. (2002) reported deficits in fear and sadness in faces for the combined 
schizophrenia and other psychotic disorders groups relative to affective psychoses groups 
and non-psychiatric controls. These findings fit with evidence that the amygdala is important 
for the recognition of fear (Adolphs, Tranel, Damasio & Damasio, 1995; Fusar-Poli, 
Placentino, Carletti, Landi, Allen, Surguladze, et al., 2009) and sadness (Adolphs & Tranel, 
2004; Aleman & Kahn, 2005) and imaging studies have shown the amygdala to be associated 
with the pathogenesis of schizophrenia (Aleman & Kahn, 2005) giving a theoretical rationale 
for specific deficits in fear and sadness in schizophrenia. However, other studies have found 
differing findings with some showing deficits for happiness, surprise and neutral (Edwards, 
Jackson & Pattison, 2002; Pomarol-Clotet, Hynes, Ashwin, Bullmore, McKenna & Laws, 
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2010). These inconsistencies may be partly explained by the range of emotion recognition 
tasks applied in the literature including a variety in the number of emotions examined, 
response times, response format and stimulus complexity (Edwards, Jackson & Pattison, 
2002).      
Moreover, although many studies have found a range of deficits in facial recognition tasks 
(see Figure 1 for an example) (Mandal et al. 1998; Edwards, Jackson & Pattison, 2002.; 
Pinkham, Penn, Perkins & Lieberman, 2003), and often with a large effect sizes (Kohler, 
Walker, Martin, Healey & Moberg, 2009), some argue that this in itself does not support the 
hypothesis that facial emotion processing is an important deficit of schizophrenia (Pomarol-
Clotet, Hynes, Ashwin, Bullmore, McKenna & Laws, 2010). This is due to individuals with 
a diagnosis of schizophrenia performing poorly on most cognitive tasks (Chapman & 
Chapman, 1973) which suggests that the disorder is associated with varying degrees of 
generalised cognitive deficit (McKenna, 2007; Reichenberg & Harvey, 2007). 
Figure 1: Emotion recognition stimuli  
 
Examples of emotion recognition stimuli of faces showing (above - left to right) anger,  
disgust, fear, (below – left to right) happiness, sadness, surprise. 
Pomarol-Clotet, Hynes, Ashwin, Bullmore, McKenna & Laws, 2010.  
 
There is an ongoing debate regarding relationship between facial emotion recognition and 
cognitive impairments. This debate concerns itself with whether facial emotion recognition 
is secondary to general neurocognitive impairment (Kohler, Bilker, Hagendoorn, Gur & Gur, 
2000; Addington, Saeedi & Addington, 2006), or whether this deficit goes beyond 
neurocognition (Edwards, Jackson & Pattison, 2002; Kohler, Turner, Bilker, Brensinger, 
Siegel & Kanes, et al., 2003; Kohler, Walker, Martin, Healey & Moberg, 2009). Some argue 
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that there is growing evidence that social cognition is distinct, although closely related, to 
neurocognition (Eack, Mermon, Montrose, Miewald, Gur & Gur, et al., 2009; Sergi, 
Rassovsky, Widmark, Reist, Erhart & Braff, et al., 2007). Given this, it is reasonable to 
hypothesise that facial emotion recognition may be an independent vulnerability marker for 
psychosis. 
On the other hand, supporting a relationship between generalized cognitive deficits and 
emotion processing, Pomarol-Clotet et al. (2010) recruited patients with a diagnosis of 
schizophrenia who did not show significant impairments in IQ. Additionally, they matched 
schizophrenia patients and controls on age, sex and estimated IQ (pre-morbid IQ in the 
patients). Faces showing emotions of anger, sadness, fear, disgust, surprise and happiness 
were presented (Figure 1). No deficits in emotion recognition accuracy were found, however 
the schizophrenia patients showed slower reaction times when responding to these emotions 
relative to controls. The authors argue that even the slower reaction times cannot be taken as 
evidence of deficits in emotion recognition as slowing of reaction times has been found to 
be a general feature of schizophrenia (Schatz, 1998). However, this claim was not 
investigated in their design and remains unsubstantiated. One possible way of addressing 
this would be to present a range of neurocognitive stimuli and record reaction times for all 
stimuli to assess whether slowing of reaction times are generalised or domain specific. 
 
1.6 Cognition and Functioning in Schizophrenia  
 
Impairments in social and occupational functioning are hallmarks of schizophrenia (Couture 
et al., 2006; McGurk & Meltzer, 2000). Deficits in functioning are largely responsible for 
the burden of psychotic disorders to patients, families, carers and wider society (Jungbauer, 
Wittmund, Dietrich & Angermeyer, 2004; Knapp, Mangalore & Simon, 2004; Ohaeri, 2003; 
Perlick, Rosenheck, Kaczynski, Swartz, Cañive & Lieberman, 2006; Magaña, Ramírez 
García, Hernández & Cortez, 2007). Impairments in functioning reduce independence, 
quality life, educational attainment and productivity (Fleischhaker, Schulz, Tepper, Martin, 
Hennighausen & Remschmidt, 2005). Impairments in social and role functioning appear to 
be the most significant in that individuals have difficulty in forming and/or maintaining 
traditional societal roles such as a worker, friend, parent, spouse or student (Nanko & 
Moridaira, 1993; Hutchinson, Bhugra, Mallett, Burnett, Corridan & Leff, 1999; Horan, 
Subotnik, Snyder & Nuechterlein, 2006; Harvey, 2013). Therefore, it is important to 
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understand the mechanisms and factors which lead to and maintain functional disability in 
individuals with psychosis.     
There is substantial evidence in schizophrenia literature that neuro-cognitive and social 
cognitive impairments are highly associated with poor occupational and social outcomes 
(Green, Kern, Braff & Mintz, 2000; Hooker & Park, 2002; Fett, Viechtbauer, Dominguez, 
Penn, van Os & Krabbendam, 2011) making them a potential target for combining illness-
specific symptomatology with at-risk criteria to improve sensitivity for transition to 
psychosis. For this reason, there have been various attempts at finding specific domains 
which appear to be the most important for functional impairment with the aim to target such 
domains for treatment. For example, one study analysed if neurocognition and clinical status 
could predict real life functioning for individuals with a diagnosis of schizophrenia (Tabarés-
Seisdedos, Balanzá-Martínez, Sánchez-Moreno, Martinez-Aran, Salazar-Fraile & Selva-
Vera, 2008). A longitudinal study assessed individuals at baseline and at one year follow up. 
They found that global functioning one year later was predicted by a composite cognition 
score and the specific domains of verbal memory, motor speed and vocabulary. Moreover, 
individuals who were at first episode of schizophrenia showed large generalised cognitive 
deficits and relative deficits in memory and executive functioning which were related to 
functional impairment (Bilder, Goldman, Robinson, Reiter, Bell, Bates & Geisler, 2000; 
Riley, McGovern, Mockler, Doku, ÓCeallaigh, Fannon et al., 2000). A recent systematic 
review and meta-analysis of social and neuro-cognitive factors in relation to functional 
outcomes in patients with a diagnosis of non-affective psychosis found that social cognition 
has a stronger relation to community functioning than neuro-cognitive factors (Fett, 
Viechtbauer, Dominguez, Penn, van Os & Krabbendam, 2011). 
 
1.7 Neurobiology of Schizophrenia 
 
Researchers have strived to identify the underlying biological mechanisms which would lead 
to such an abnormal developmental trajectory described by neurodevelopmental models 
which would result in the symptomology of schizophrenia. However, the causal mechanisms 
leading to schizophrenia are still unclear.  
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1.7.1 Anatomical/Neuroimaging Studies 
 
The past decades of research have resulted in mounting support for the neurodevelopmental 
model of schizophrenia. Much of this support comes from research into at-risk groups of 
schizophrenia. Physiological differences in neuropathological and neuroimaging studies of 
patients with chronic schizophrenia have also been observed in those who are experiencing 
their first episode and those who are deemed to be at-risk of developing schizophrenia. This 
suggests that neurobiological signatures cannot be an effect of chronicity but instead 
highlight that there are related to the development of the disorder itself (Harrison, 2008). 
Some of the main findings from the last 40 years of research are summarised here.         
Neuroimaging: The first finding came from computer tomography (CT) studies in a 
landmark paper from Johnestone et al. (Johnstone, Frith, Crow, Husband & Kreel, 1976) 
which discussed the enlargement of the lateral ventricles in patients which chronic 
schizophrenia. This confirmed earlier pneumoencephalographic findings (Huber 1955; 
1961) which renewed interest in the neurobiology and neuropathology of schizophrenia. 
This led to an explosion of studies using CT and magnetic resonance imaging (MRI) to 
investigate brain structure and function in the search for neural correlates of schizophrenia. 
Findings highlighted a range of quantitive structural differences in the brains of individuals 
diagnosed with schizophrenia including abnormalities in brain regions such as the 
hippocampus and parahippocampal gyrus, insula, thalamus, cingulate gyrus, and prefrontal 
and temporal cortices (Vita, Peri, Silenzi & Dieci, 2006). A mega-analysis which 
summarised 32 meta-analyses of MRI studies reported reduced grey matter in individuals 
with chronic schizophrenia and FEP in the frontal lobe gyri, thalamus, cingulate cortex, 
insula, postcentral gyrus and medial temporal regions and additionally increased volume of 
ventricles and cavum septum pellucidum (Shepherd, Laurens, Matheson, Carr & Green, 
2012). Additionally, there is a marked reduction in whole brain volume.  
More recently these findings have been extended to first episode and at-risk groups (Pantelis, 
Velakoulis, McGorry, Wood, Suckling, Phillips, et al., 2003). A meta-analysis of individuals 
who are at-risk of developing schizophrenia found that at-risk subjects showed reduced grey 
matter volumes in the prefrontal cortex bilaterally (right middle frontal gyrus, left medial 
frontal gyrus), temporal (right superior temporal), limbic (bilateral anterior cingulate 
regions, bilateral parahippocampal/hippocampal) and parietal (left precuneus) regions 
(Fusar-Poli, Borgwardt, Crescini, Deste, Kempton, Lawrie, et al., 2011). These regions have 
also been found to be structurally altered in schizophrenia spectrum disorders (Tan, Callicott 
& Weinberger, 2009; Boyer, Phillips, Rousseau & Ilivitsky, 2007). Moreover, grey matter 
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reductions in the right inferior frontal gyrus and superior temporal gyrus have been found in 
UHR subjects who later transition to frank psychosis but not in those who don’t (Fusar-Poli, 
Borgwardt, Crescini, Deste, Kempton, Lawrie, et al., 2011) suggesting a possible 
neurobiological predictor of schizophrenia. Figure 2 shows baseline differences between 
high risk individuals who did and did not transition to psychosis during a 2-year follow-up 
(Koutsouleris, et al., 2009).  
Figure 2: Structural brain alterations observed in HR individuals (n = 182) and matched controls 
(n = 167). 
   
Baseline differences between HR individuals who did (HR-T, n = 48) and did not (HR-NT, n = 134) transition to 
psychosis during 2-year follow-up. The HR-T group show less gray matter volume than the HR-NT group in the left 
parahippocampal gyrus, bordering the uncus. The plot shows mean gray matter volumes for the 2 HR subgroups at each 
site (1 indicates London, United Kingdom; 2, Basel, Switzerland; 3, Munich, Germany; and 4, Melbourne, Australia). 
Error bars represent SD (Koutsouleris, et al., 2009). 
 
The causes of these differences in grey matter have been at the centre of ongoing debate 
regarding whether such differences are caused by: 1) early developmental insults and are 
stable over time or 2) by a progressive loss due to effects of the disorder. To address this 
issue, research is investigating those who are at genetic risk of schizophrenia, at-risk groups 
and individuals with chronic schizophrenia.  
 
1.7.2 Neurotransmitters: Glutamate/GABA 
 
Investigations into mechanisms which underlie the loss of brain volume in schizophrenia 
have suggested that the glutamatergic system is involved (Harrison and Weinberger, 2005). 
Increased hippocampal glutamatergic levels in unmedicated patients with schizophrenia 
have been correlated with hippocampal volume reductions (Kraguljac, White, Reid & Lahti, 
2013). Glutamate (Glu) is the most abundant excitatory neurotransmitter in the central 
nervous system (Fonnum, 1984) and has been found to be reduced in individuals with 
chronic schizophrenia and increased in medication naïve patients (Poels, Kegeles, 
Kantrowitz, Javitt, Lieberman, Abi-Dargham & Girgis, 2014). Therefore, it is conceivable 
that although glutamate levels are increased in the early stages of the disorder, they decrease 
after antipsychotic medication treatment (Marsman, Mandl, Klomp, Bohlken, Boer, 
Andreychenko et al, 2017).  
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A recent meta-analysis which included a total of 647 schizophrenia patients and 608 controls 
across 28 studies also reported reduced Glu. Interestingly, group-by-age associations found 
that Glu decreased faster with age in schizophrenia patients compared to controls. It appears 
that FEP-groups show an increase in Glu whilst individuals with chronic schizophrenia show 
a decrease in Glu (Port & Agarwal, 2011). Researchers have hypothesised that initially Glu 
levels are increased which then leads to excitotoxicity which then in turn brings about 
neuronal death which can be seen as decreases in N -Acetylaspartic acid (NAA). NAA can 
be seen as a marker of viable neurons, axons and dendrites (Merugumala, Ramadan, Keenan, 
Liao, Wang & Lin, 2014).  
A recent meta-review also reported increases in glutamine (Gln) in schizophrenia (Marsman, 
van den Heuvel, Klomp, Kahn, Luijten & Hulshoff Pol, 2011) which could be due to deficits 
in glutaminase (the enzyme that converts Gln into Glu) which would explain the decreased 
glutamate and the increased Gln shown in studies of patients with chronic schizophrenia. 
However, it is argued that the results of these studies are questionable as the majority of 
studies have not had their methods validated (Merugumala, Ramadan, Keenan, Liao, Wang 
& Lin, 2014). 
 
Additionally, it has been found that aberrant glutamatergic neurotransmission in 
schizophrenia is related to a dysfunction in N -methyl- d -aspartate (NMDA) receptors. This 
is supported by findings that NMDA-receptor agonists, such as ketamine and phencyclidine, 
induce psychotic symptoms in healthy volunteers (Javitt and Zukin 1991).  
 
Differences in γ-Amino Butyric Acid (GABA) neurotransmission, the major inhibitory 
neurotransmitter in the central nervous system (CNS) (Merugumala, Ramadan, Keenan, 
Liao, Wang & Lin, 2014), have been found to be an important feature in the pathophysiology 
of schizophrenia which are evidenced by reduced GABA synthesis. This is supported 
through decreased activity of GAD67 expression (Gonzalez-Burgos, Hashimoto & Lewis, 
2010).  
Moreover, research has found that GABA receptors may be upregulated which suggests a 
compensatory response to the decrease in GABA levels (Jarskog, Gilmore, Glantz, Gable, 
German, Tong & Lieberman, 2007). Reductions in GABA-level have been linked to 
cognitive performance as a recent study reported a reduction of GABA in chronic 
schizophrenia patients in the anterior cingulate which was correlated with lower attention 
performance (Rowland, Kontson, West, Edden, Zhu, Wijtenburg & Barker, 2012).  
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Studies investigating glutamate and GABA levels are becoming increasingly sophisticated 
with the advancements of ever more powerful imaging methods. A recent 7 T 1H-MRS study 
found that patients with schizophrenia showed significantly lower prefrontal GABA levels, 
However, no differences were found in glutamate. Interestingly, GABA was negatively 
correlated with total IQ in patients with schizophrenia. The authors argue that this suggests 
processes involving GABA in the prefrontal cortex are distinguished from glutamate and 
that GABA may have a compensatory role in the prefrontal cortex in high functioning 
individuals with a diagnosis of schizophrenia (Marsman, Mandl, Klomp, Bohlken, Boer, 
Andreychenko et al, 2017).   
Differences in GABA/Glutamate-levels may, however, be potentially confounded by the 
effects of antipsychotic medication. A recent study found that the concentration of GABA 
measured in the anterior cingulate was negatively correlated with the dose of medication. 
Any significant differences in GABA did not hold once the patients on such medications had 
been excluded from analysis (Tayoshi, Nakataki, Sumitani, Taniguchi & Shibuya-Tayoshi, 
et al., 2010).  
 
1.7.3 Neurodevelopmental vs Neurodegenerative 
 
These findings along with the identification of genetic and environmental risk factors have 
not only helped shape an understanding of the aetiology of schizophrenia but have provided 
evidence for an ongoing fundamental debate around the trajectory of dysfunction in 
schizophrenia spectrum and other psychotic disorders. Traditionally, schizophrenia was 
considered a neurodegenerative disorder. Kraepein’s description of dementia praecox 
encapsulates the neurodegenerative theory which posits that progressive neurodegeneration 
is the driving force behind the mental decline of the disorder (Kochunov & Hong, 2014). 
However, to this day there is little evidence for this hypothesis. Nonetheless, it is often 
proposed degeneration could be explained by as excessive synaptic pruning or inflammation 
(Howes, Fusar-Poli, Bloomfield, Selvaraj, McGuire, 2012).  
Neurodevelopmental models argue that genetic and environmental factors are at play during 
prenatal, perinatal and early adolescent stages that impact upon the typical course of 
neurodevelopment (Lewis & Levitt, 2002; Rapoport, Giedd, & Gogtay, 2012). 
Neurodevelopmental models view schizophrenia as being the final stage of such abnormal 
neurodevelopmental processes which begin many years before the onset of the disorder. 
Cognitive and longitudinal studies have been crucial in developing the understanding of 
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neurodevelopmental processes and risk factors associated with these. A main finding of these 
studies has been that individuals who go on to develop schizophrenia have impaired 
cognitive and motor performance even in childhood (Dickson, Laurens, Cullen & Hodgins, 
2012). However, impairment of cognition, language and motor function are common in 
childhood and are generally seen to be risk factors to a wide range of psychopathological 
outcomes in adulthood and thus not specific to schizophrenia (Johnstone, Ebmeier, Miller, 
Owens & Lawrie, 2005; Lawrie, Olabi, Hall, & Mcintosh, 2011). The neurodevelopmental 
hypothesis of schizophrenia strongly supports the idea that cognitive dysfunction is a core 
feature of the illness (Gold, 2004; Green, Nuechterlein, Gold, Barch, Cohen, Essock, et al., 
2004).  
 
1.8 Prodromal Phase, Basic Symptoms and UHR 
 
Many of the symptoms of schizophrenia can be observed long before the full manifestation 
of the disorder (Beiser, Erickson, Fleming & Iacono 1993; Yung & McGorry, 1996).  This 
period, known as the prodromal phase, involves changes in mood, such as anxiety and/or 
depression, social withdrawal, attenuated subthreshold psychotic symptoms (APS), 
disorganisation and cognitive deficits. ‘At-risk or ‘at-risk mental state’ (ARMS) (Yung & 
McGorry, 1996a; Yung & McGorry, 1996b) criteria have been developed, i.e. clinical high-
risk (CHR), also known as high-risk (HR), and ultra-high-risk (UHR) (Fusar-Poli., Deste, 
Smieskova, Barlati, Yung & Howes, et al., 2012). A model of the onset of psychosis from 
the clinical high-risk state is shown in Figure 3. This shows the course of the prodromal 
phase from its initial stages into first episode psychosis. It is important to note that meeting 
criteria for ARMS is considered a risk factor for developing psychosis but does not, however, 
mean that transition to psychosis is inevitable (Yung & McGorry, 1996a; Yung & McGorry, 
1996b). Importantly, one of the outcomes of research in ARMS groups has highlighted the 
potential development of both psychotic and non-psychotic disorders, again highlighting this 
phase as an important target for early intervention.    
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Figure 3: Model of psychosis onset from the clinical high-risk state.            
 
Model of psychosis onset from the clinical high-risk state. The higher the line on the y-axis, the 
higher the symptom severity. Fusar-Poli et al. (2013). 
 
Schizophrenia and related disorders typically manifest during late adolescence/early 
adulthood which is an important transitional time in terms of biological development as well 
as social, psychological and occupational development. Moreover, emerging evidence 
suggests that the debilitating negative and cognitive symptoms are evident even before a full 
manifestation of schizophrenia. Cortical changes during this time have been associated with 
motivational, social and cognitive dysfunctions which once manifested are difficult to 
improve, even after successful treatment of positive symptoms (McGorry, Yung & Phillips, 
2001). Given this, early intervention, and a focus on negative symptoms, is important not 
only for early detection to avoid a delay in treatment but also to identify phase-specific 
interventions for individuals in the early stages of the disorder (Chang, 2011). Such 
interventions could not only delay onset and limit functional decline, but also potentially 
avoid the development of frank psychosis altogether (Fusar-Poli et al, 2012).  
Two main approaches have emerged from research involving ARMS groups, the basic 
symptom approach (BS) and the attenuated psychotic symptoms (APS) approach. Basic 
symptom approach encapsulates the early stages of the prodrome which consists of subtle 
sub-clinical changes in mood, cognition, motivation and motor action. The UHR 
classification conceptualises the APS approach. Criteria for UHR status are aimed at 
capturing experiences in the later stages of the prodromal phase which includes experiences 
of attenuated psychotic symptoms. The focus of such research is on the transition to full 
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manifestation of psychosis with an aim to identifying biomarkers, outcomes and targets for 
early intervention. 
The term prodromal was first used in 1932 by Mayer-Gross whose work was an influential 
force for the seminal work of Huber and Gross (1989) in first promoting the concept of basic 
symptoms (Schultze-Lutter, Addington, Ruhrmann & Klosterkötter, 2007). More recently, 
work involving basic symptoms has been the focus of the German Early Detection Team 
which has highlighted the importance of basic symptoms as predictors of psychosis (Häfner, 
Maurer, Ruhrmann, Bechdolf, Klosterkötter, Wagner et al., 2004; Schultze-Lutter, 
Ruhrmann & Klosterkötter, 2006). Basic symptoms are experienced as subtle, sub-clinical, 
subjective disturbances over the domains of perception, thought processes, attention, 
language, affect and motor action. They have been found to be present before the first 
episode of psychosis, between psychotic episodes, and after. Basic symptoms have also been 
found to be present during psychotic episodes themselves and are understood to be the first 
psychopathological expression of the underlying symptoms associated with the development 
of psychosis. These are phenomenologically distinct from attenuated psychotic symptoms 
measured in UHR (Schultze-Lutter, Addington, Ruhrmann, Klosterkotter & 2007). Unlike 
UHR criteria, basic symptoms are not associated with any unusual thought content and 
individuals are not at the stage of reality testing. In addition, individuals may be away of the 
experiences psychopathological nature (Schultze-Lutter, 2009).    
Basic symptoms are measured using the Schizophrenia Proneness Instrument-Adult version 
(SPI-A) (Schultze-Lutter, Addington, Ruhrmann & Klosterkotter, 2007) and the 
Schizophrenia Proneness Instrument-Child and Youth version (SPI-CY) (Schultze-Lutter, 
Marshall & Koch, 2012). These measure self-perceived, subjective disturbances around the 
domains of drive, stress-tolerance, affect, motor disturbance and body perception. Items are 
clustered around two sub-categories of COPER (10 cognitive-perceptive basic symptoms) 
and COGDIS (9 cognitive criteria) with the latter being the most predictive of later transition 
to psychosis (Schultze-Lutter, Klosterkötter, Picker, Steinmeyer & Ruhrmann, 2007). It has 
been demonstrated in a help seeking population that a subset of basic symptoms 
demonstrated a good predictive value for developing frank schizophrenia in the next 9-10 
years. The highest predictive accuracy was associated with perceptive and cognitive basic 
symptoms (KlosterKotter, Hellmich, Steinmeyer & Schultze-Lutter, 2001).  
A UHR classification generally defines the later stages of the prodrome and requires one of 
the following to meet criteria: attenuated psychotic symptoms (APS); brief limited 
intermittent psychotic episode (BLIPS); a genetic risk factor plus marked functional decline 
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(genetic risk and deterioration syndrome (GRD) and unspecified prodromal symptoms 
(UPS) (Fusar-Poli et al, 2012). A number of measures have been developed to assess for 
these subgroups within UHR status. The most widely used being the Comprehensive 
Assessment of At-Risk Mental States (CAARMS) (Yung, Phillips, Simmons, Ward, 
Thompson, French, & McGorry, 2006) and the Structured Interview for Prodromal 
Symptoms (SIPS) and its companion Scale of Prodromal Symptoms (SOPS) (Miller, 
McGlashan, Rosen, Cadenhead, Cannon, Ventura, McFarlane et al., 2003).  
UHR criteria have been the most extensively researched approach and recruitment has 
focused primarily on help-seeking/clinical populations recruited through prodromal and 
early intervention clinics. More recently, researchers have increasingly used combined BS 
and UHR criteria that has produced improved prediction rates for psychosis (Ruhrmann, 
Schultze-Lutter, Salokangas, Heinimaa, Linszen & Dingemans, et al., 2010). In terms of 
neuro-cognitive studies, cognitive deficits appear to be less pronounced in studies using the 
basic symptom approach, intermediate in studies using the UHR approach and most 
pronounced in studies using a combined approach (Fusar-Poli et al, 2012).  
 
1.9 Cognition in CHR 
 
Cognitive deficits are considered as vulnerability markers of psychosis (Bora, Lin, Wood, 
Yung, McGorry & Pantelis, 2014) and can be useful treatment targets. As cognitive 
dysfunctions are already present at first episode, this suggests that such dysfunctions may be 
a marker of psychosis before the manifestation of the disorder. There is substantial evidence 
of cognitive deficits in UHR groups (Fusar-Poli et al, 2012) and evidence that such deficits 
exist before the prodromal phase (Bora & Murray, 2014). Cognitive functioning in patients 
who were diagnosed with schizophrenia later in life, as well as their siblings, were found to 
be stable from age 4 to 7 suggesting that cognitive deficits are stable vulnerability markers 
throughout the premorbid phase (Cannon, Bearden, Hollister, Rosso, Sanchez & Hadley, 
2000). 
Generally, the profile of cognitive deficits in UHR samples reflects those of frank 
schizophrenia. Significant impairments have been found in various domains of 
neurocognitive functioning including working memory, attention, speed of processing, 
verbal memory executive functions have been found in UHR populations (Seidman, 
Giuliano, Smith, Stone, Glatt, Meyer, et al., 2010; Bora et al, 2014; Kelleher, Clarke, 
Rawdon, Murphy & Cannon, 2013). Early studies of cognitive functioning in UHR 
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populations have found that CHR-UHR-individuals showed impairments in cognition 
relative to controls and these deficits were less substantial than in FEP (Hawkins, Addington, 
Keefe, Christensen, Perkins, Zipurksy, et al. 2004).  
In the largest CHR study to date, Seidman et al. (2016) found CHR-individuals to be 
significantly impaired in all neurocognitive domains compared to controls. In a sample of 
689 CHR-participants and 264 controls, they found the largest deficits to be in attention and 
working memory abilities, and declarative memory abilities which showed large effect sizes 
(see Figure 4). CHR-individuals who transitioned to psychosis were significantly impaired 
in attention and working memory abilities, and in declarative memory abilities relative to 
CHR-individuals who did not transition to psychosis (Seidman, Shapiro, Stone, Woodberry, 
Ronzio, Cornblatt, et al., 2016).      
Figure 4: Effect Sizes (Cohen d) for Individual Tests Adjusted for Age, Site, and Maternal Education for 
Clinical High-Risk Converters to Psychosis (CHR + Cs), Clinical High-Risk Nonconverters (CHR − NCs), 
and Healthy Controls (HCs) 
 
Effect sizes are rank ordered from largest to smallest. ACPT indicates Auditory Continuous Performance Test (QA are 
simply the letters; Q3A, the number of letters between an “A” and a “Q”); BACS, Brief Assessment of Cognition in 
Schizophrenia symbol coding; BVMT-R, Brief Visuospatial Memory Test–Revised; CPT-IP, Continuous Performance 
Test–Identical Pairs; HVLT-R, Hopkins Verbal Learning Test–Revised; LNS, Letter Number Span; NAB, 
Neuropsychological Assessment Battery mazes; PAM, Paired Associate Memory; UPSIT, University of Pennsylvania 
Smell Identification Test; WASI, Wechsler Abbreviated Scale of Intelligence; WMS-3, Wechsler Memory Scale–Third 
Edition spatial span; and WRAT-4, Wide Range Achievement Test 4. Taken from Seidman, Shapiro, Stone, Woodberry, 
Ronzio, Cornblatt, et al., 2016. 
 
Hawkins et al. (2004) found a group of 36 high risk (HR) individuals to be no different in 
intellectual performance relative to controls on 3 out of 4 subtest, however, the HR group 
did perform more poorly on the 4th subtest, the Digit Symbol test which measures processing 
speed. This may be due to the small sample size and the possibility that the study was 
underpowered leading to an increased chance of Type II errors. They found the HR group to 
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be significantly impaired in all other tests with the most pronounced deficits being in 
measures of visual attention, set shifting and verbal fluency. Notably, the HR group were 
not found to have the same level of impairment as individuals who were at first episode of 
psychosis. This suggests a process of cognitive deterioration which may go along with the 
progression to frank psychosis. However, there is not robust evidence for this so far. Another 
study found a UHR group to be significantly impaired in tasks of spatial working memory, 
spatial span and delayed matching-to-sample (Wood, Pantelis, Proffitt, Phillips, Stuart & 
Buchanan, et al., 2003). Similarly, Smith, Park & Cornblatt (2006) found spatial working 
memory to be significantly impaired in age and IQ matched adolescents at clinical high risk 
of psychosis relative to controls.  
However, findings have been somewhat inconsistent with differences in profiles being 
reported and the more prominent domains differing across studies. In these studies, spatial 
working memory has been found to be impaired in UHR groups and associated with negative 
symptoms (Wood, Pantelis, Proffitt, Phillips, Stuart & Buchanan, et al., 2003). Many studies 
have found at-risk groups to be impaired in each domain relative to controls (e.g. Bora et al, 
2014; Hou, Xiang, Wang, Everall, Tang & Yang, et al., 2016) although inconsistent in which 
impairment is most prominent. Follow up studies have suggested that certain domains may 
indicate stable vulnerability markers (e.g. sustained attention) (Francey, Jackson, Phillips, 
Wood, Yung & McGorry, 2005) whereas others may be predictive of transition to psychosis 
(e.g. verbal IQ, processing speed, verbal memory, working memory) (Brewer, Francey, 
Wood, Jackson, Pantelis, Phillips, et al., 2005; Lencz, Smith, McLaughlin, Auther, 
Nakayama, Hovey, et al., 2006; Seidman, Giuliano, Smith, Stone, Glatt & Meyer, et al., 
2010). There has been support for both processing speed and verbal memory as the main 
predictors for transition to psychosis (Lencz, Smith, McLaughlin, Auther, Nakayama, 
Hovey, et al., 2006; Lin, Wood, Nelson, Brewer, Spiliotacopoulos, Bruxner, et al., 2011; 
Fusar-Poli, Deste, Smieskova, Barlati, Yung, Howes et al., 2012). However, these findings 
remain inconsistent (Keefe, Perkins, Gu, Zipursky, Christensen & Lieberman, 2006). 
Moreover, processing speed and verbal memory have been found to endure throughout the 
course of the illness and have been associated with the major disability which is associated 
with schizophrenia (Green & Harvey, 2014).     
It has been argued that processing speed is the core cognitive deficit in psychosis and 
possibly the driving cognitive deficits in other domains (Dickinson, 2008). However, it has 
also been found that the effect size of processing speed can be moderated by a number of 
variable, most importantly by anti-psychotic medication (Knowles, David & Reichenberg, 
2010). This has led to some debate as to as to the role of processing speed as a core deficit 
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of schizophrenia. Support for the speed of processing hypothesis in UHR has been 
consistently demonstrated. One study conducted a population based assessment of 
prodromal symptoms in adolescents. Those who met UHR criteria were found to show 
deficits in many areas with processing speed being the most pronounced (see Figure 5) 
(Kelleher, Murtagh, Clarke, Murphy, Rawdon & Cannon, 2013).  
Figure 5: Profile of cognitive function of CHR-individuals relative to controls 
           
The non-psychiatric control group was set to 0 and standard deviation to 1. Error bars show standard errors of the mean.                
* p < 0.05, **p < 0.01, ***p < 0.001. Taken from Carrión, Goldberg, McLaughlin, Auther, Correll & Cornblatt, 2011. 
 
 
The progressiveness of neuro-cognitive deficits over the prodromal and frank psychosis 
trajectory is still being debated with some reporting no change over time, others suggesting 
that deficits get progressively worse (Brewer, Wood, Phillips, Francey, Pantelis & Yung, et 
al., 2006). One study compared cognitive functioning of two at risk groups (one group met 
criteria for predictive basic symptoms and the other for UHR criteria based on SIPS/SOPS) 
with those at first episode and help seeking controls (Simon, Cattapan-Ludewig, Zmilacher, 
Arbach, Gruber, Dvorsky et al., 2007). They found that all 4 groups performed below 
normative levels with the at-risk groups being intermediate between normative values and 
first episode. The basic symptom group was found to be comparable in cognitive functioning 
to the help seeking controls but more impaired that the UHR group. Other studies have 
suggested that neurocognitive deficits are stable throughout the prodrome, treatment phase 
and first episode (Hawkins, Keefe, Christensen, Addington, Woods, Callahan, et al., 2008) 
whilst a recent meta-analysis showed some improvement after first episode (Bora & Murray, 
2014). These inconsistencies may be reflective of confounds such as medication, 
psychological treatments, poor physical health and institutionalisation (Fusar-Poli, Deste, 
Smieskova, Barlati, Yung & Howes, et al., 2012). This highlights a benefit of conducting 
research with medication naïve UHR samples as many of these confounds can be avoided.   
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Reasons for these inconsistencies may include varying measures across studies, different 
classifications of ‘at-risk’ or differing UHR subcategories. This is an important issue as it 
has been suggested that impairments differ across UHR sub-groups with individuals who are 
further along the prodromal trajectory being the most significantly impaired (Fusar-Poli et 
al., 2012). False positives and comorbidity are other important factors to consider when 
studying at-risk groups. The majority of participants who meet UHR criteria will not go on 
to develop psychosis (Fusar-Poli et al., 2012; Cannon, Cadenhead, Cornblatt, Woods, 
Addington & Walker, et al., 2008) with transition rates between 10-30 % (Fusar Poli et al, 
2012). Moreover, this suggests that impaired neurocognitive functioning may be more 
indicative of being at risk to a wider scope of psychopathology rather than being exclusive 
to psychosis (Velthorst, Nieman, Linszen, Becker, de Haan & Dingemans, et al., 2009; Lin, 
Yung, Nelson, Brewer, Riley & Simmons, et al., 2013). Therefore, it is important to identify 
subclinical illness specific symptomatology in which to improve sensitivity and specificity 
in at risk groups (Ballon, Kaur, Marks & Cadenhead, 2007).   
A recent meta-analysis (Bora & Murray, 2014) found UHR to be impaired in every domain 
of cognition relative to controls. The most robust deficits were observed for symbol coding 
task (a measure of processing speed), visuospatial working memory and a smell 
identification task all with medium effect sizes. Cognitive deficits were found to be 
significantly more severe in those who later developed psychosis.  
An earlier meta-analysis (Fusar-Poli et al, 2012) observed significant impairments in general 
intelligence relative to controls and an overall impairment in neuro-cognitive functioning. In 
relation to transition to psychosis the most prominent deficits were observed in visual and 
verbal memory. Overall there were no impairments found in the domain of processing speed. 
However, there was a significant difference found in the digit symbol substitution task 
(symbol coding task) when compared to controls. UHR individuals were best distinguished 
from controls on the performance of the digit symbol substitution task, letter number 
sequencing task and continuous performance task. This suggests that although speed of 
processing was found to be non-significant overall, this may be due to the differing methods 
of measuring processing speed, or that the digit symbol substitution task is measuring 
something more specific. There was also a significant difference in the overall domain of 
social cognition relative to controls.  
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1.10 Social Cognition in CHR 
 
CHR studies have found deficits emotion recognition, theory of mind and social perception 
(Thompson, Bartholomeusz & Yung, 2011). However, compared to existing literature on 
neurocognition, the number of studies examining social cognition in CHR-populations is 
small. Studying emotion recognition in CHR-populations is important given the abundant of 
deficits in schizophrenia (Mandal, Pandey & Prasad, 1998; Aleman & Kahn, 2005; Trémeau, 
2006) that are associated with impairments in social skills (Hooker & Park, 2002; Pinkham 
& Penn, 2006; Ikebuchi, 2007). In CHR, a similar profile of impaired facial emotion 
recognition has been reported (Thompson, Papas, Bartholomeusz, Allott, Amminger, 
Nelson, et al., 2012; Amminger, Schäfer, Klier, Schlögelhofer, Mossaheb, Thompson, et al., 
2012a; Amminger, Schafer, Papageorgiou, Klier, Schlogelhofer, Mossaheb, et al., 2012b; 
van Rijn, Aleman, de Sonneville, Sprong, Ziermans, Schothorst, et al., 2011; Green, 
Bearden,  Cannon, Fiske, Hellemann, Horan, Kee, et al., 2012) and deficits remained 
significant after controlling for important covariates/confounders. This suggests that 
emotion recognition deficits may emerge during or even before the prodrome. A recent meta-
analysis found that UHR participants demonstrate significant moderate deficits in emotion 
recognition in faces (van Donkersgoed, Wunderink, Nieboer, Aleman & Pijnenborg, 2015). 
They reported that the majority of studies did not find a correlation between social cognitive 
impairments and transition to psychosis suggesting that general social cognition may not be 
a useful marker of transition to psychosis. However, some studies suggest there may possible 
predictive value in specific forms of social cognition, in particular the recognition of specific 
emotions.     
Allott, et al. (2014) found lower accuracy of faces showing neutral emotion and higher 
accuracy of faces showing fear to be predictive of transition to psychosis within 12 months 
after controlling for baseline positive, negative and global symptoms and functioning. This 
supports previous findings from schizophrenia and UHR-literature which suggests that 
emotion recognition may be a trait marker of psychosis as UHR-groups perform significantly 
poorer than controls on a facial recognition task and not significantly different from first 
episode and multiple episode individuals (Addington, Penn, Woods, Addington, Perkins, 
2008a; Amminger, Schäfer, Klier, Schlögelhofer, Mossaheb & Thompson, et al, 2012). 
However, Green et al (2012) found CHR-individuals to be significantly impaired in emotion 
recognition relative to controls and less impaired relative to first episode and chronic 
schizophrenia groups.  
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Many studies have found a particular deficit in the identification of neutral emotion 
(Addington, Penn, Woods, Addington, Perkins, 2008a; Eack, Mermon, Montrose, Miewald, 
Gur & Gur, et al., 2010; van Rijn, Aleman, de Sonneville, Sprong, Ziermans & Schothorst, 
et al., 2011), although this is somewhat inconsistent (Pinkham et al. 2007). Amminger et al., 
(2011) compared groups of UHR-participants, individuals at first episode of psychosis and 
controls on an emotion recognition task. They found that UHR-individuals showed deficits 
in emotion recognition in both faces and voices, specifically fear and sadness, relative to 
controls, and that UHR group deficits were comparable to first episode. van Rijn et al (2011) 
observed deficits in emotion recognition in a sample of UHR individuals when compared to 
controls. Specifically, UHR individuals made more errors in recognising faces showing no 
emotion. Further analysis showed that UHR individuals would misattribute faces showing 
no emotion for anger.     
However, findings for emotion recognition in at-risk for psychosis literature are conflicting. 
There have been a number of studies which did not observe any deficits in CHR-UHR 
populations. Pinkham et al. (2007) compared groups of individuals at CHR for psychosis, 
those at first episode of psychosis, those with chronic schizophrenia and controls. They 
found that emotion recognition deficits were observed only in the first episode and chronic 
schizophrenia groups. Findings from phase 2 of the North American Prodromal Longitudinal 
Study (NAPLS-2) did not find any significant differences between those at CHR (N=675) 
and controls after controlling for IQ and age (Barbato, Liu, Cadenhead, Cannon, Cornblatt 
& McGlashan et al., 2015). These findings were similar to Thompson et al. (2012) who 
observed no significant differences of emotion recognition between those at UHR for 
psychosis and controls when controlling for age, gender and IQ.     
In a 5-year longitudinal study of UHR individuals Kim et al (2011) found that combining 
social-cognitive and neurocognitive variables significantly predicted transition to psychosis. 
This, combined with evidence from schizophrenia studies (e.g. Sergi et al., (2007) reported 
social cognition as contributing to predictions of functional outcome in chronic 
schizophrenia) suggests that such deficits are evident throughout the entire course of the 
illness, including the prodromal phase therefore can be considered as risk markers for 
psychosis. Given the potential of social cognition as a predictive factor, it is important to 
include measures of social cognition in UHR research.  
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1.11 Cognition and functioning 
      
Recently research has investigated levels of functioning in those who are at-risk for 
psychosis and the relationship between neurocognitive functioning and functional outcomes. 
Addington et al (2008b) found a CHR group of individuals to be significantly impaired in 
social functioning relative to controls but comparable to first episode and multiple episode 
groups. In addition, the CHR group performed poorer than controls on role functioning but 
better than the multiple episodes group. In studies that have investigated functional outcomes 
in UHR groups, social functioning outcomes appear to be more stable than role functioning 
and has been shown to be associated with transition to psychosis (Cornblatt, Auther, 
Niendam, Smith, Zinberg & Bearden et al, 2007; Velthorst, Nieman, Linszen, Becker, de 
Haan & Dingemans et al., 2010). This suggests that along with neuro-cognitive and social 
cognitive factors, deficits in social functioning are evident before the onset of psychosis and 
may be a trait marker of the disorder. 
Studies have looked at the association between neurocognition and functioning in at-risk 
groups with conflicting findings. In UHR samples, it has been found that impairments in 
processing speed and verbal learning and memory are predictive of current social 
functioning which is independent of negative and positive symptom severity. However, 
general functioning was associated with negative symptoms and not neurocognitive 
functioning (Niendam, Bearden, Johnson, McKinley, Loewy, & O'Brien et al., 2006). After 
an eight month follow up period, improvements in functioning were not associated with the 
severity of neurocognitive performance at baseline, but with improvements in processing 
speed and visual learning and memory (Niendam, Bearden, Zinberg, Johnson, O'brien & 
Cannon, 2007). On the other hand, another study found that improvement in neurocognitive 
performance was not associated with social functioning measured by Global Assessment of 
Functioning (GAF) scores in an at-risk sample with six months follow up (Jahshan, Heaton, 
Golshan & Cadenhead, 2010). 
A recent study extended this research and examined the development of impairments in 
cognition and their relationship to functioning (Carrión, Goldberg, McLaughlin, Auther, 
Correll & Cornblatt, 2011). The CHR group had significant impairment in neurocognition 
particularly in the domains of processing speed, verbal memory, executive function and 
working memory. Moreover, impairments in both social and role functioning were present 
that were related to neurocognitive performance independent of positive symptoms. More 
specifically, speed of processing was the most significantly impaired and predictive of 
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poorer social and role functioning at baseline relative to controls. This suggests that the 
relationship between neurocognition and functioning exists before the onset of frank 
psychosis and is not an outcome of the illness. Lin, et al. (2011) observed in a sample of 
UHR individuals (N=203) that poor functional outcome was associated with impaired 
baseline performance in verbal learning and memory, processing speed, attention and verbal 
fluency but not global cognitive performance. Additionally, they found that reduced 
performance on a verbal story recall task combined with negative symptoms at baseline was 
the best predictor of poor outcome later on. Positive psychotic symptoms and GAF scores at 
baseline were not associated with poor outcome later on. Importantly, they found that poor 
functional outcomes were associated with specific neurocognitive domains, regardless of 
transition to psychosis.  
 
1.12 Early interventions in high risk 
 
The identification of UHR-populations has been combined with interventions that could 
potentially stop the transition to psychosis or delay onset of psychotic symptoms. A 
randomised control trial of cognitive behavioural therapy (CBT) for the prevention of 
psychosis in individuals at UHR (Morrison, French, Walford, Lewis, Kilcommons, Green et 
al. 2004) found that 6 months of CBT significantly reduced the likelihood of transitioning to 
psychosis within a 12-month period and improved the severity of positive symptoms. Some 
benefits were still evident at 3-year follow up, specifically a reduced likelihood of being 
prescribed anti-psychotic medication. However, CBT did not affect the likelihood of 
transition to psychosis over the 3-year follow up period (Morrison, French, Parker, Roberts, 
Stevens, Bentall & Lewis, 2006). A randomised controlled trial compared CBT to supportive 
therapy and assessed individuals at follow up on attenuated positive symptoms, negative 
symptoms, anxiety, depressions and social functioning. After 18 months, only individuals in 
the supportive therapy group transitioned to psychosis. However, the difference in transition 
rates did not reach significance (Addington, Epstein, Liu, French, Boydell & Zipursky, 
2011). Both groups improved in the severity of attenuated positive symptoms (although 
positive symptoms improved more quickly in the CBT group), anxiety and depression but 
social functioning and negative symptoms did not improve. This suggests that social 
functioning is independent of positive symptoms however may be related to negative 
symptoms of psychosis. 
 
39 
 
Pharmaceutical studies have also found promising results. A randomised controlled trial of 
an active treatment of risperidone (1-3 mg/day) along with modified CBT compared to a 
needs-based intervention (McGorry, Yung, Phillips, Yuen, Francey, Cosgrave et al, 2002). 
They found that significantly transition rates were significantly lower in the active treatment 
group (9.7% vs 36%). Another study looked at the efficacy of the antipsychotic olanzapine 
in a randomised, double-blinded placebo controlled trail. They found that at one-year follow-
up 16% of the olanzapine treatment group had transitioned to psychosis compared to 35% 
of the placebo group however this difference was not significant. Moreover, the olanzapine 
treatment group overall showed greater improvements in symptoms than did the placebo 
group (McGlashan, Zipursky, Perkins, Addington, Miller, Woods et al., 2006). However, a 
recent meta-analysis reported that there is no reliable evidence as to whether psychosocial 
(such as CBT), anti-psychotic medication, or potentially neuroprotective agents (such as 
Omega -3 fatty acids) are the most effective in preventing psychosis in at-risk groups. The 
safest treatments are then recommended which are psychosocial interventions and Omega -
3 fatty acids.  
 
A meta-analysis of interventions in those who are UHR for developing psychosis found that 
overall such interventions are effective (van der Gaag, Smit, Bechdolf, French, Linszen, 
Yung, et al., 2013). They found that the risk of onset was reduced by 54% to 52% within the 
first 12 months and by 37% to 35% between 2 to 4 years. These diminishing results, although 
show efficacy at delaying onset, suggest that such treatment may not be effective at 
preventing psychosis. Similarly, Fusar-Poli et al. (2013) reported that overall preventative 
treatments in psychosis are feasible and can be effective. There are many large scale clinical 
trials currently being carried out which will provide much needed evidence for best clinical 
practice in at-risk states (Morrison, Stewart, French, Bentall, Birchwood, Byrne, et al., 
2011).   
 
Early intervention studies have also investigated the course of neurocognitive functioning in 
the prodrome and at first episode of psychosis (Hawkins, Keefe, Christensen, Addington, 
Woods, Callahan, et al., 2008). An olanzapine double blind treatment study found that 
neither the anti-psychotic nor transition to psychosis altered the course of neurocognitive 
function. Overall, it has been demonstrated that although pharmacological treatments have 
had some success at treating positive symptoms, there has been little success in treating 
negative symptoms and cognitive impairments (Keefe, Bilder, Davis, Harvey, Palmer, Gold, 
et al., 2007).    
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1.13 Aims 
 
CHR literature has reported robust deficits in neurocognitive functioning (Fusar Poli et al., 
2012; Bora & Murray, 2014) and well reported but somewhat conflicting deficits in social 
cognition (van Donkersgoed, Wunderink, Nieboer, Aleman & Pijnenborg, 2015). Emotion 
recognition has emerged as a potentially important factor for CHR populations, although, 
findings are conflicting with more research needed (van Donkersgoed, Wunderink, Nieboer, 
Aleman & Pijnenborg, 2015). Fewer studies have assessed the relationship between 
neurocognitive functioning and functional outcomes and have found differing findings 
(Niendam, Bearden, Johnson, McKinley, Loewy, & O'Brien et al., 2006; Carrión, Goldberg, 
McLaughlin, Auther, Correll & Cornblatt, 2011). There is a gap in the literature regarding 
the relationship between emotion recognition and functional outcomes.   
This study will explore the relationship between neurocognitive and social cognitive 
variables with current psychosocial functioning. The association of neurocognitive 
impairments and functional parameters are somewhat understudied in CHR-literature and 
with even less literature existing in relation to social cognitive factors in relation to 
functioning.  
The main questions that will be addressed: 
1) What are the differences in cognitive, social cognitive and psychosocial functioning in 
those who are at-risk of psychosis relative to controls?  
2) To what extent does neuro- and social cognition explain poor functioning in the CHR 
population? 
We expect to find that, relative to controls, CHR participants will show significant 
impairments in many domains of cognition with the most prominent impairments being 
found in processing speed. In addition, we expect that CHR participants will display 
impaired global, social and role functioning at baseline and that processing speed may be a 
predictor of poor functioning. In relation to emotion recognition, we expect to find that CHR 
participants will have poorer emotion recognition abilities relative to controls with a 
potential for recognition of faces showing neutral emotion being the most impaired. In 
addition, we will explore the relationship between emotion specific recognition and current 
psychosocial functioning in individuals who are CHR for psychosis. To the best of our 
knowledge this is the first study to investigate this association, therefore, this part of the 
analysis is exploratory. 
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2. METHODS 
 
2.1 Design 
 
The data presented in this thesis are part of a longitudinal the Youth Mental Health Risk and 
Resilience (YouR) study. This thesis will utilise a cross-sectional design to assess the neuro- 
and social cognitive functioning of individuals who are CHR for psychosis relative to 
controls. Clinical characteristics and demographic data will also be assessed. Finally, we will 
assess the relationship between neuro- and social cognitive factors and functional parameters 
at baseline. 
The principal investigator obtained ethical approval and the study is being carried out 
according to the Research Governance Framework for Health and Community Care (Second 
edition, 2006).  
 
2.2 Participants 
 
We recruited 110 participants who met CHR criteria (mean age:  22, SD: 3.07) and 44 
controls (mean age:  22, SD: 4.16). We recruited potential participants from the general 
population through a website (www.your-study.org.uk), flyers and public transport 
advertisement. An email containing information about the study and a link to the study 
website was also circulated through a number of Glasgow universities and colleges. We 
developed close relationships with NHS Greater Glasgow and Clyde and NHS Lothian 
services including General Practitioners, primary care and secondary mental health services 
which included ESTEEM First Episode Psychosis Service (Glasgow), the Early Psychosis 
Support Service (Lothian), Community Mental Health Teams, and non-statutory (third 
sector) mental health services. Potential participants were initially informed of the study by 
a member of their direct care team either face to face or by post. Potential participants could 
then either obtain information through leaflets or were directed to the study website to 
complete the online screening questionnaire. Inclusion/exclusion criteria were assessed prior 
to and during the screening visit. See Table 1 for inclusion / exclusion criteria.    
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Table 1: Inclusion and exclusion criteria for CHR-participants and controls  
Inclusion criteria (CHR) Exclusion criteria (CHR) 
Written informed consent An existing neurological disorder 
Male or non-pregnant female ≥16 years of age > 35 years of age 
UHR-criteria according to CAARMS/SIPS or SPI-A Metal implants in body parts 
Normal to corrected vision Pregnancy 
 Suicidal ideation 
Inclusion criteria (controls) Exclusion criteria (controls) 
Written informed consent An existing neurological disorder 
Male or non-pregnant female ≥16 years of age > 35 years of age 
Normal to corrected vision Metal implants in body parts 
 Pregnancy 
 1st degree relative with a diagnosis of Schizophrenia 
 Suicidal ideation 
 
 
2.3  Measures 
 
2.3.1 Pre-screening 
 
Online screening questionnaire: This comprised the 16-item prodromal questionnaire (PQ-
16) (Ising, Veling, Loewy, Rietveld, Rietdijk & Dragt, et al., 2012) and assessed attenuated 
psychotic symptoms. This is a self-report questionnaire designed to measure attenuated 
psychotic symptoms and identify individuals who are at risk of developing psychosis. The 
PQ-16 was developed from the full 92 item prodromal questionnaire (PQ) (Loewy, Bearden, 
Johnson, Raine & Cannon, 2005). Secondly, a 9 item-scale for the assessment of perceptual-
cognitive anomalies (PCA) was included. Informed consent was taken at the point of the 
online screening. Criteria to qualify for a screening interview were 6 or more on the PQ-16 
items and/or 3 items on the PCA-scale.   
 
2.3.2 CHR Assessment  
 
A combination of basic symptoms and UHR criteria were used to assess clinical high-risk 
status. This combined approach has been shown to produce improved prediction rates for 
psychosis (Ruhrmann, et al., 2010). 
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The Schizophrenia Proneness Instrument, Adult Version (SPI-A) (Schultze-Lutter, 
Addington, Ruhrmann & Klosterkötter, 2007) is a semi-structured interview which measures 
diagnostic criteria of basic symptoms. This consists of 3 subscales and totals 33 items of 
cognitive, perceptual, and motor disturbances assessed on a 7-point severity scale (score, 0-
6). The maximum frequency of occurrence during the preceding 3 months is the guiding 
criterion. Based on these criteria, individuals are diagnosed as COPER and/or COGDIS. 
COPER and COGDIS refer to two partially overlapping basic symptom criteria which define 
the initial stage of the prodrome of psychosis. A COPER diagnosis is based on the 10 
cognitive-perceptive basic symptoms and is based on the predictive accuracy of single basic 
symptoms. COGDIS represents cognitive disturbances, a cluster of 9 cognitive basic 
symptoms which were repeatedly selected as the most predictive of later transition to 
psychosis (Schultze-Lutter, Klosterkötter, Picker, Steinmeyer & Ruhrmann, 2007).     
 
The CAARMS (Yung et al, 2006) is a semi-structured interview that assess attenuated 
psychotic criteria for an at risk mental state diagnosis. CAARMS ratings are made three 
subscales 1) Positive symptoms consisting of unusual thought content and non-bizarre ideas 
2) Perceptual Abnormalities and 3) Disorganised speech (see Table 2 for diagnostic criteria).  
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Table 2: Diagnostic criteria for ARMS categories measured by the CAARMS  
BLIPS* 1) A Global Rating Scale score of 6 on Unusual Thought Content, Non-bizarre Ideas, or 
Disorganized Speech; or 5–6 on Perceptual Abnormalities 
 2) A Frequency Scale score of 4–6 on the relevant symptom scale 
3) Symptoms are present for less than one week 
4) Symptoms resolve without medication 
5) Symptoms occurred during the past year 
 
Attenuated 
symptoms 
 
 
A. Subthreshold intensity 
1) A Global Rating Scale score of 3–5 on Unusual Thought Content or Non-Bizarre Ideas; or 
3–4 on Perceptual Abnormalities; or 4–5 on Disorganized Speech 
2) A Frequency Scale score of 3–6 on the relevant symptom scale 
3) Symptoms are present for more than one week 
4) Symptoms occurred during the past year 
B. Subthreshold frequency: 
1) A Global Rating Scale score of 6 on Unusual Thought Content, Non-Bizarre Ideas, or 
Disorganized Speech; or 
5–6 on Perceptual Abnormalities 
2) A Frequency Scale score of 3 on the relevant symptom scale 
3) Symptoms occurred during the past year 
 
State-plus-
trait 
1) History of psychosis in a first-degree relative or identification of Schizotypal Personality 
Disorder 
2) 30% drop in GAF** score from pre-morbid level, sustained for at least one month, within the 
past year or a GAF score of 50 or less for at least the past year 
UHR inclusion criteria and subcategories for CAARMS *BLIPS, Brief Limited Intermittent Psychotic 
Symptoms; **GAF, Global Assessment of Functioning 
 
2.3.3 Functioning 
 
Global Assessment of Functioning (GAF) is used to measure the severity of illness in 
psychiatry (Aas, 2011) (see appendix 1). This measure gives a single score based on the most 
severe symptoms and functioning during the past month. In addition, GF Social and GF Role 
scales were used to measure social and occupational functioning (Cornblatt, Auther, 
Niendam, Smith, Zinberg & Bearden et al, 2007). These scales were developed to be 
complementary to each other. Both scales are scored on a range of one to ten with one being 
the most severely impaired and ten indicating superior functioning (Cornblatt, Auther, 
Niendam, Smith, Zinberg & Bearden et al, 2007). Anchor points for GF social and GF Role 
can be found in appendices 2 & 3. A benefit of these scales is that they avoid confounding 
functioning with psychiatric symptoms. The GF social assesses relationships with peers and 
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family members along with peer conflict. The GF role assesses performance and amount of 
support needed in an individual’s specific role with questions relating to school, work or 
housekeeping duties.  
 
2.3.4 Premorbid Adjustment Scale  
 
The Premorbid Adjustment Scale (PAS) (van Mastrigt & Addington, 2002) measures 
premorbid functioning from a developmental perspective. Good premorbid adjustment is 
conceptualised as the achievement of age-appropriate developmental and social milestones. 
This is examined over 4 areas of development: sociability and withdrawal, peer 
relationships, ability to function outside of the family and capacity to form intimate socio-
sexual ties. These are measured over 4 developmental stages (childhood [up to age 11], early 
adolescence [12–15 years], late adolescence [16–18 years] and adulthood [19 years of age 
and older]). 
 
2.3.5 Cognition 
 
The Brief Assessment of Cognition in Schizophrenia (BACS) version 3.1 (Keefe, Gold, 
Goldberg & Harvey, 1999) was administered to assess cognition. The BACS has been 
developed for clinical trials where the domains of cognitive function assessed are those 
which are consistently found to be impaired in schizophrenia. The BACS measures verbal 
memory, working memory, motor speed, attention, executive functions and verbal fluency. 
The measure requires less than 35 minutes to complete (Keefe, Goldberg, Harvey, Gold, Poe 
& Coughenour, 2004). Table 3 describes the BACS domains and their related tasks and 
measures. 
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Table 3: BACS domains and related tasks. 
Domain Task and measure  
Verbal memory and learning Task – list learning. A list of 15 words is presented. 
Participants are asked to recall as many of these words as 
possible. This procedure is repeated 5 times. Measure – 
Verbal recall (number of words recalled). Range - 0-75  
Working memory Task – Digit sequencing. The researcher read out clusters 
of numbers of increasing length. Participants were asked 
to reorder the clusters to be in order from lowest to highest 
with the longest sequence recalled consisting of 8 digits. 
Measure – number of correct responses. Range – 0-28.  
Motor speed: Task – Token motor task. 100 plastic tokens are placed on 
a table. Participants are asked to use both hand to 
simultaneously pick up 2 tokens at the same time and place 
them into a container as quickly as possible. Measure – 
number of tokens correctly placed into the container within 
the 60 seconds timeframe. Range – 0-100. 
Verbal Fluency: Task – Semantic fluency. Participants are given 60 seconds 
to name as many words as possible within a given 
category. Measure – number of words named. Task – 
Letter fluency. In 2 separate trials, participants are given 
60 seconds to name as many words as possible beginning 
with a specific letter. Measure – number of words named.  
Executive function: Task – Tower of London. Participants are shown two 
pictures simultaneously. Each picture displayed three balls 
of different colours arranged on three pegs. The balls in 
each picture were arranged differently. Participants were 
asked to give the number of moves it would take for the 
arrangement of balls in the first picture to look like the 
arrangement of balls in the second picture. Measure – 
number of correct responses. Range – 0-20.  
Speed of processing: Task – symbol coding. Participants were presented with a 
key describing how unique symbols correspond with 
numerals 1 – 9. They were asked to fill out the 
corresponding number beneath a series of symbols as 
quickly as possible. Participants had 90 seconds to code as 
many as possible. Measure – Number of correctly coded 
symbols.              
 
 
Additional tasks from the University of Pennsylvania Computerized Neuropsychological 
Testing Battery (PennCNB) were administered. 
Penn Continuous Performance Test (PCPT; Kurtz et al., 2001): The PCPT is a standard CPT 
paradigm where participants are asked to respond to a set of 7-segment displays which are 
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presented 1 per second. Following an example trial, participants are asked to respond by 
pressing the space bar when they see a fully formed digit (NUMBERS) or letter (LETTERS). 
The test lasts for 6 minutes with NUMBERS forming the initial 3 minutes and LETTERS 
forming the final 3 minutes. The CPT paradigm is widely used for measuring vigilance and 
has been used in detecting genetic susceptibility to psychosis (Chen & Faraone, 2000). 
The Letter N-Back task (LBN; Ragland et al., 2002):  Letter are presented for 500ms and 
then gives and additional 2000ms for the participant to respond by pressing the spacebar or 
not. There are 3 conditions to this task. The 0-Back – instructions are to press the spacebar 
when the letter “X” appears; 1-Back- press the spacebar when the letter presented is the same 
as the previous letter; and 2-Back – press the spacebar when the letter presented is the same 
as the one prior to the previous letter. Following an example trial, participants test begins 
and participants are given 3 blocks of each condition in a predetermined order. There is a 
total of 135 trials.   
The 40-item facial affect identification test (ER40; Gur et al., 2002):  was used as a measure 
of emotion identification. There are 5 conditions consisting of 4 emotions (happy, sad, fear, 
angry) and a no emotion condition (neutral). There are 8 facial displays for each condition 
and the participant is given a multiple-choice format to identify the emotion. The facial 
stimuli are balanced for age, ethnicity and gender.  
 
2.4 Procedure  
 
All visits were carried out by trained research assistants and postgraduate students (MSc and 
PhD). Participants first completed the 25-item online screening questionnaire. Informed 
consent was taken for online participation. Those who met online criteria were then invited 
to attend a screening interview at the University of Glasgow Psychology department. 
Informed consent was taken before the screening interview which included demographics, a 
brief clinical history and interviews for SPI-A and CAARMS. GF: Role GF: Social measures 
were completed during a follow-up visit with the neurocognitive assessments being 
completed on a third visit. Participants first completed the BACS followed by the three 
PennCNB tasks. Instructions for the BACS were read aloud verbatim by a researcher whilst 
the PennCNB tasks included on screen instructions and practice sessions.   
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3. RESULTS 
All statistical analysis was performed using IBM SPSS version 24. Each individual subscale 
of cognitive tasks was assessed for normality and raw test scores were standardized by 
creating z scores using the means and standard deviations of non-psychiatric controls. Data 
for the Letter N Back test were found to be significantly non-normally distributed therefore 
the standardization process was not conducted for this subscale. A BACS global score was 
calculated by summing all the standardized BACS domain scores and again re-standardizing. 
3.1 Demographics and Functioning  
To examine differences in demographics between groups t tests were performed for 
continuous data and a chi square test was used to examine differences for nominal data. 
Table 4: Baseline demographic and clinical characteristics of Clinical high-risk participants and 
controls  
Characteristic Control 
(N=44) 
SD CHR           
(N=110) 
SD F df P Cohen’s d 
Age (years) 22.11 3.07 21.85 4.16 1.40 1,152 0.71  
Years of education 16.17 2.71 15.06 3.15 4.12 1,142 0.04* 0.41 
GAF  88.69 6.72 60.36 13.84 149.67 1,141 <0.001*** 2.6 
GF: Social 8.87 0.41 7.65 1.01 53.57 1,137 <0.001*** 1.58 
GF: Role 8.59 0.79 7.47 1.12 32.6 1,138 <0.001*** 1.16 
PAS         
     Childhood  0.05 0.06 0.17 0.14 24.41 1,137 <0.001*** -1.11 
     Early adolescence 0.08 0.05 0.2 0.14 28.46 1,135 <0.001*** -1.14 
     Late adolescence 0.1 0.09 0.21 0.14 16.38 1,130 <0.001*** -0.93 
 N % N % X2 df P  
Gender     1.52 1 0.22  
     Male 16 36% 29 26%     
     Female 28 64% 81 74%     
Medication status     53.1 5 <0.001***  
     None 44 100% 51 46%     
     Anti-psychotic _ _ 1 1%     
     Mood stabiliser  _ _ 1 1%     
     Anti-depressant  _ _ 23 21%     
     Other _ _ 15 14%     
     Multiple _ _ 19 17%     
Occupational status     1.59 5 0.91  
     Full time paid 3 7% 5 6%     
     Part time paid 2 5% 4 4%     
     Voluntary 1 2% 1 1%     
     Student  36 81% 91 83%     
     Unemployed  2 4% 9 7%     
Baseline demographics and clinical characteristics of the control and UHR groups. *p<0.05, **p<0.01, ***p<0.00. Effect 
sizes are classified as small (d = 0.2), medium (d = 0.5), and large (d ≥ 0.8). 
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Table 4 summarises the baseline demographic and clinical characteristics of CHR and 
control participants. CHR and controls did not differ significantly on age (at consent), gender 
ratio or occupational status. Participants did significantly differ on years of education, 
premorbid adjustment in childhood, early and late adolescence and medication status. Non-
psychiatric controls had a higher mean of years of education and lower scores on the 
premorbid adjustment scale (higher scores reflect poorer premorbid adjustment).  
The clinical high-risk group demonstrated significantly poorer social (p < 0.001, Cohen’s d 
=1.58) and role functioning (p < 0.001, Cohen’s d =1.16) as well as lower GAF scores (p < 
0.001, Cohen’s d =2.6). Social functioning for the CHR group ranged from (5 - Serious 
impairment in social/interpersonal functioning to 10- Superior social/interpersonal 
functioning), role functioning ranged from (4 - Major impairment in role functioning to 9 - 
Above average role functioning) and GAF ranged from (38 - Some serious symptoms or 
impairment in functioning to 95- No symptoms).   
At the time of consent the 46% of CHR-participants were not taking any medication, 21% 
were taking anti-depressants, 14% were taking other types of medication than mentioned in 
table 2, 17% were taking multiple types of medication, 1% were taking anti-psychotics and 
1% were taking mood stabilisers. At time of testing 83% of CHR-participants were students, 
7% were unemployed, 6% were in full time work, 4% in part time work and 1% in voluntary 
work.  
ANOVAs were performed to assess differences between CHR-participants meeting differing 
CHR-categories (SPI-A, CAARMS, and SPI-A+CAARMS) and to assess differences 
between CHR-participants who were recruited through clinical services and those who were 
not. 
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Table 5: Mean scores for BACS total, GAF, social and role functioning for CHR-
individuals meeting differing CHR-criteria and recruitment paths.     
 CAARMS SPI-A CAARMS 
+ SPI-A 
F df P 
N (%) 32 (31%) 24 (22%) 42 (42%)    
BACS -0.96 -0.41 -0.55 0.9 2,94 0.41 
GAF 61.72 68.38 56.21 7.98 2,95 0.001*** 
Social Functioning 7.53 7.82 7.64 0.51 2,93 0.61 
Role Functioning  7.53 7.82 7.23 2.06 2,94 0.13 
 CHR CS  CHR 
Other 
 F df P 
N (%) 13 (12%) 97 (88%)     
BACS -1.77 -0.55  6.5 1,92 0.012* 
GAF 56.38 61.59  1.96 1,101 0.17 
Social Functioning 7.17 7.72  3.2 1,98 0.077 
Role Functioning  6.83 7.55  4.42 1,99 0.038* 
 CHR CS (CHR-participants recruited through clinical services), CHR Other (CHR-participants not recruited through 
clinical services). * p < 0.05, *** p < 0.001. 
Table 5 shows clinical characteristics between the CHR-subgroups and referrals vs non-
referrals. In the clinical high-risk group 42% met criteria for CAARMS and SPI-A items, 
31% for CAARMS only and 22% for SPI-A only. Differences in BACS global score, GAF, 
social and role functioning between CHR-subgroups were assessed using ANOVA. CHR-
subgroups were found not to have a significant effect of BACS global score (F (2,94) = 0.9, 
p = 0.41). No differences were found for social (F (2,93) = 0.51, p = 0.61) or role (F (2,94) 
= 2.06, p = 0.13) functioning. There was a significant difference between CHR-subgroups 
for GAF (F (2,95) = 7.98, p = 0.001). Using Hochberg’s GT2 test, post hoc analysis was 
conducted to assess the effect of CHR-subgroup on GAF scores. The SPI-A subgroup (mean 
GAF: 68.38) were significantly different to SPI-A+CAARMS subgroup (mean GAF: 56.21), 
p < 0.001. 
Differences between CHR-participants recruited through clinical services and CHR-
participants who were not recruited through clinical services were assessed using ANOVA 
(see Table 5). Those who were recruited though clinical services performed more poorly on 
BACS total score (F (1,92) = 6.5, p = 0.012), role functioning (F (1,99) = 4.42, p = 0.038) 
with a statistical trend observed for social functioning (F (1,98) = 3.2, p = 0.077) compared 
to those who did not. No significant differences were observed for GAF.  
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3.2 Neuro-Cognition   
Individual ANOVAs were performed on individual neurocognitive domains to assess for 
differences between CHR participants and controls. 
Table 6: Neurocognitive performance of Clinical High-risk participants. 
Domain UHR 
Mean 
N (CHR/ 
Control) 
  SD        Df    F P Cohens 
d 
 BACS 
Verbal Memory 0.009 97 / 41 1.29 1,136 0.002 0.97  
Motor Speed -0.96 97 / 41 1.14 1,136 21.72 <0.001*** 0.89 
Processing Speed -0.51 97 / 41 1.17 1,136 5.81 0.017* 0.46 
Verbal Fluency -0.07 97 / 40 0.98 1,135 0.15 0.7  
Executive 
Function 
-0.21 95 / 41 1.24 1,134 0.91 0.34  
Working 
Memory 
-0.05 97 / 41 1.26 1,136 0.05 0.82  
BACS Global -0.69 94 / 40 1.54 1,132 6.74 0.011* 0.53 
 Penn CNB 
Emotion 
Recognition 
-0.13 87 / 26 0.96 1,111 0.35 0.56  
Emotion 
Recognition RT 
0.71 87 / 26 1.73 1,111 3.93 0.05* -0.96 
Attention -0.79 87 / 26 2.79 1,111 2.65 0.11  
Attention RT -0.25 87 / 26 1.1 1,111 0.1 0.3  
Working 
Memory RT 
-0.02 86 / 26 0.88 1,110 0.009 0.93  
 Mean 
Rank 
N (CHR/ 
Control) 
Mean 
Rank 
Df U P  
Working 
Memory 
(LNB task) 
53.53 86 / 26 68.6 113 829.5 0.031*  
Mean standardised scores of UHR-participants across domains of neuro-cognitive functioning including statistical p 
values, Cohen’s d and effect sizes. RT (response times).  *p < 0.05, ** p < 0.01 ***p < 0.001. Effect sizes are classified 
as small (d = 0.2), medium (d = 0.5), and large (d ≥ 0.8). 
Table 6 summarises the individual univariate ANOVAs carried out for each cognitive 
domain. Individual ANOVAs revealed that CHR-participants (n = 94; control n = 41) were 
significantly impaired in the domains of motor speed (F (1,136) = 21.72, p <0.001), 
processing speed (F (1,136) = 5.81, p = 0.017), and BACS global score (F (1,132) = 6.74, p 
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= 0011). From the PennCNB tasks, CHR-participants (n = 86; control n = 26) were impaired 
in emotion recognition response times (F (1,111) = 3.93, p = 0.05). A non-parametric test 
was used for the PennCNB test of working memory (LNB task) as these data were negatively 
skewed. This suggests a possible ceiling effect. A Mann-Whitney U test found that working 
memory was significantly impaired in the CHR-group relative to controls (U (113) = 829.5, 
p = 0.031). Large effect sizes were found for motor speed (d = 0.89), BACS global (d = 0.53) 
and emotion recognition RT (d = -0.96) and a medium effect size was shown for processing 
speed (d = 0.46). 
Between group differences were assessed for emotion specific recognition with individual 
ANOVAS. 
Table 7: Emotion specific recognition of Ultra High-risk participants 
Emotion UHR Mean N (CHR/ 
Control) 
SD Df F P Cohens 
d 
Anger -0.27 87 / 26 1.28 1,111 9.31 0.32  
Fear -0.22 87 / 26 0.88 1,111 0.01 0.92  
No Emotion -0.24 87 / 26 1.19 1,111 0.89 0.35  
Happy -0.27 87 / 26 1.24 1,111 1.01 0.32  
Sad 0.17 87 / 26 0.91 1,111 0.62 0.42  
Emotion 
RT  
UHR Mean  SD Df F P Cohens 
d 
Anger 0.16 87 / 26 1.32 1,124 0.30 0.59  
Fear 0.65 87 / 26 2.06 1,124 2.43 0.12  
No Emotion 0.68 87 / 26 2.54 1,124 1.78 0.19  
Happy 1.16 87 / 26 1.72 1,124 10.35 0.02* -0.81 
Sad 0.76 87 / 26 2.92 1,124 1.68 0.21  
Mean of standardised scores of the UHR-participants for emotion specific recognition including statistical p values, 
Cohen’s d and effect sizes. RT (response times). *p < 0.05. Effect sizes are classified as small (d = 0.2), medium (d = 
0.5), and large (d ≥ 0.8). 
 
Table 7 summarises the individual univariate ANOVAs carried out for emotion specific 
recognition. CHR-individuals did not differ significantly in the recognition of specific 
emotions relative to controls. CHR-participants (n = 87; control n = 26) were significantly 
slower in their response times for in recognising happy faces (F (1,124) = 10.35, p = 0.02) 
which showed a large effect size (d = -0.81).  
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3.3 Cognition and Functioning  
 
Stepwise multiple linear regressions were performed to assess the relationship between 
neurocognitive domains and functional outcomes. Predictor variables included were the 
domains of neurocognition which were found to be significantly impaired. These were motor 
function, processing speed, BACS composite and emotion recognition response times.  
 
Table 8: Linear regression results for the effects of neurocognitive performance on GAF, social and 
role functioning at baseline in CHR-participants 
GAF 
Variable B SE Β P ΔR2 
Emotion 
Recognition 
RT 
-2.3 0.88 -.28 0.01* 0.07 
Social Functioning 
Emotion 
Recognition 
RT 
-0.2 0.06 -.32 0.003** 0.09 
Role functioning 
BACS 
Global 
0.22 0.08 .31 0.004** 0.09 
RT (response times). *p < 0.05, **p < 0.01. 
 
Table 8 shows that emotion recognition response times was a significant predictor of GAF 
and social functioning at baseline. BACS global score was a significant predictor of role 
functioning. Emotion recognition RT accounts for 7% and 9% of the variance for GAF and 
social functioning respectively. BACS global score accounts for 9% of the variance for role 
functioning.  
 
Additional exploratory analyses were carried out for the effect of emotion specific response 
times on functional outcomes in the CHR-group. Response times for each emotion were 
entered into a stepwise linear regression model.  
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Table 9: Linear regression results for the effects of emotion specific response times on GAF, social 
and role functioning at baseline in CHR-participants 
GAF 
Variable B SE Β p ΔR2 
Sad RT -1.3 0.6 -0.4 0.04* 0.1 
Social Functioning 
Fear RT -0.2 0.05 -0.3 0.002** 0.1 
Role Functioning 
Fear RT -0.2 0.06 -.34 0.001** 0.1 
RT (response times). *p < 0.05, **p < 0.01. 
  
Table 9 shows response time for sad faces was found to be a significant predictor of GAF 
scores at baseline. Response time for fearful faces was found to be a significant predictor for 
both social and role functioning. Sad RT accounted for 10% of variance for GAF. Fear RT 
accounted for 10% of variance for both social and role functioning.   
 
 
4. DISCUSSION 
 
Neurocognitive deficits are a hallmark of schizophrenia (Keefe & Harvey, 2012) and 
evidence shows that such deficits are found in the prodromal phase of the disorder (Fusar-
Poli et al, 2013; Bora & Murray, 2014). Specifically, deficits in the areas of working 
memory, attention, speed of processing, verbal memory, executive functions and emotion 
recognitions have been reported in CHR-populations (Seidman, Giuliano, Smith, Stone, 
Glatt, Meyer, et al., 2010; Bora et al, 2014; Kelleher, Clarke, Rawdon, Murphy & Cannon, 
2013).  
This thesis aimed to extend these findings by exploring neurocognitive and social cognitive 
variables in relationship to subthreshold psychotic symptoms as well as current psychosocial 
functioning.  
The main questions in this thesis were: 
1) What are the differences in cognitive, social cognitive and psychosocial functioning in 
those who are at-risk of psychosis relative to controls?  
2) To what extent does neuro- and social cognition explain poor functioning in the CHR 
population?  
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4.1 Cognition 
 
4.1.1 Neurocognition  
 
There is a robust body of evidence for impairments in neurocognitive functioning in CHR-
populations (Fusar-Poli et al., 2012; Bora & Murray, 2014). Data from phase 2 of the largest 
CHR-study to date, the North American Prodrome Longitudinal Study (NAPLS-2), has 
shown CHR individuals to be impaired in all areas of neurocognition relative to controls 
(Seidman, Shapiro, Stone, Woodberry, Ronzio, Cornblatt, et al., 2016) with small to medium 
effect sizes. However, CHR studies have reported conflicting findings regarding the profile 
of cognitive impairment in CHR with some reporting impairments in only some domains 
(Niendam, Bearden, Johnson, McKinley, Loewy, O'Brien et al., 2006; Kelleher, Murtagh, 
Clarke, Murphy, Rawdon & Cannon, 2013).          
In the current study, we found CHR-individuals to be significantly impaired in the domains 
of emotion recognition response times (RT), motor speed, processing speed and working 
memory with medium to large effect sizes. BACS global score was also impaired. Emotion 
recognition RT was the most prominent of these followed by motor speed and finally 
processing speed. In contrast, CHR-participants were found to be intact on the digit 
sequencing task, verbal fluency, verbal memory, executive function, and Penn CNB 
measures of attention, attention response times, working memory response times and 
emotion recognition.  
These findings are partially in line with existing literature. A number of studies have reported 
processing speed to be the most prominent impairment (Carrión, Goldberg, McLaughlin, 
Auther, Correll & Cornblatt, 2011; Kelleher, Murtagh, Clarke, Murphy, Rawdon & Cannon, 
2013). Kelleher et al. (2013) found processing speed and non-verbal working memory to be 
the only domains impaired in those who met UHR criteria with processing speed being the 
most prominent of these. However, they did not report effect sizes and their sample of 
individuals meeting UHR criteria was small (n=19). Carrión et al. (2011), in a sample of 127 
treatment seeking CHR-individuals found impairments across all domains of neurocognition 
with the most prominent deficit being processing speed. The authors of these papers argue 
that these findings show support for processing speed as being central to neurocognitive 
dysfunction in CHR-participants. Our findings offer some support for this hypothesis as 
impairments in processing speed were observed in our CHR-group with a medium effect 
size.   
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Schizophrenia literature emphasise the importance of attention (Cornblatt & Keilp, 1994) 
and working memory (Park & Gooding, 2014). Evidence is emerging of deficits in 
declarative memory in first episode psychosis (Saykin, Shtasel, Gur, Kester, Mozley, 
Stafiniak, et al., 1994) and in CHR populations (Seidman, Shapiro, Stone, Woodberry, 
Ronzio, Cornblatt, et al., 2016). The domain of attention has been argued to represent a stable 
vulnerability marker in CHR-populations (Francey, Jackson, Phillips, Wood, Yung & 
McGorry, 2005; Lencz, Smith, McLaughlin, Auther, Nakayama, Hovey & Cornblatt, 2006). 
More recent data from the NAPLS-2 cohort have demonstrated impairments in working 
memory and attention in CHR-participants who later transitioned to psychosis relative to 
CHR-participants who did not transition (Seidman, Shapiro, Stone, Woodberry, Ronzio, 
Cornblatt, et al., 2016). Given the conflicting findings between our working memory tasks 
and the lack of significance for attention, our findings have not supported the hypothesis of 
the centrality of attention and working memory in CHR populations (Seidman, Shapiro, 
Stone, Woodberry, Ronzio, Cornblatt, et al., 2016). 
We found that the CHR and control groups differed significantly only in one of the working 
memory tasks in the current study which may be due to a difference in task demands. The 
BACS digit sequencing task requires participants to manipulate the order of numbers. The 
Penn CNB Letter-N-Back task involves the participant indicating when the currently 
presented stimuli match stimuli presented n (0, 1 or 2) steps earlier. CHR-individuals showed 
deficits in the latter of these two tasks. Our findings suggest that our CHR-participants may 
display a deficit which is task specific. Similar findings have been reported in other domains. 
In a meta-analysis Fusar-Poli et al. (2012) did not find UHR-participants to be impaired in 
processing speed, however, there was a significant difference between UHR-participants and 
controls specifically for the Digit Symbol Substitution Test (symbol-coding task).   
Additionally, impairments in verbal fluency and memory have been reported as important 
factors in CHR-groups (Fusar-Poli, Deste, Smieskova, Barlati, Yung & Howes, et al., 2012). 
In a meta-analysis, Fusar-Poli et al. (2012) found verbal fluency and memory to be 
associated with subsequent transition to psychosis. Neuropsychological findings from phase 
1 of the NAPLS project (NAPLS-1) reported that general neuropsychological functioning 
did not contribute uniquely to the prediction of transition to psychosis beyond clinical 
symptoms, however, poorer verbal memory was found to predict more rapid transition 
(Seidman, Giuliano, Meyer, Addington, Cadenhead, Cannon & Woods, 2010).  In our 
sample, we did not find verbal fluency or verbal memory to be significantly different 
between groups.   
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BACS global cognition did not differ significantly between differing CHR-criteria (SPI-A, 
CAARMS, and SPI-A+CAARMS). However, a significant difference was observed for 
BACS global cognition between CHR-participants who were recruited through clinical 
services vs CHR-participants who were not. This fits with existing literature which shows 
that more severe neurocognitive impairments are associated with poorer outcomes for CHR-
individuals (Seidman, Shapiro, Stone, Woodberry, Ronzio, Cornblatt, et al., 2016). 
Together, these findings highlight neurocognitive impairments as a putative treatment target 
for early intervention. However, sample sizes for these groups were small and statistical 
analysis may have been underpowered.    
   
4.1.2 Social cognition 
 
We expected to find that CHR-participants would be characterized by poorer emotion 
recognition relative to controls. This hypothesis was partially supported. In our sample, 
emotion recognition RT was found to be the most significantly impaired in CHR-participants 
when compared with controls. Emotion recognition is an important factor in CHR-
populations as it has been argued that deficits in emotion recognition may be a trait marker 
for schizophrenia (Edwards, Jackson & Pattison, 2002) and is a predictor for transition to 
psychosis (Allott, Rice, Bartholomeusz, Klier, Schlögelhofer & Schäfer, et al., 2014). 
Specifically, Allott et al. (2014) found that lower accuracy of recognising neutral faces and 
higher accuracy for fearful faces are predictive of transition to psychosis within a 12-month 
period. Many studies have found a specific deficit in the identification of neutral emotion in 
CHR-populations (Addington, Penn, Woods, Addington, Perkins, 2008a; Eack, Mermon, 
Montrose, Miewald, Gur & Gur, et al., 2010; van Rijn, Aleman, de Sonneville, Sprong, 
Ziermans & Schothorst, et al., 2011) although this is not always the case. Pinkham et al. 
(2007) found that CHR-individuals did not differ from controls on emotion recognition tasks. 
Findings from non-clinical psychosis (NCP-brief psychotic like experiences which occur in 
5-7% of the general population; van Os et al., 2009) have shown similar results. Pelletier et 
al. (2013) found a group of individuals who scored high for non-clinical psychosis to be 
significantly impaired in the recognition of fearful face relative to a group of individuals 
who scored low for non-clinical psychosis.   
In the current study, accuracy of emotion recognition was intact while the speed with which 
emotions were processed was decreased. Overall, the CHR group were significantly slower 
than controls and this deficit was specifically driven by an impairment to respond to happy 
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faces. Although the majority of studies investigating emotion recognition in CHR-samples 
have found deficits (Addington, Penn, Woods, Addington, Perkins, 2008a; Eack, Mermon, 
Montrose, Miewald, Gur & Gur, et al., 2010; van Rijn, Aleman, de Sonneville, Sprong, 
Ziermans & Schothorst, et al., 2011; Allott, Rice, Bartholomeusz, Klier, Schlögelhofer & 
Schäfer, et al., 2014), some studies have also reported intact reactions to emotional stimuli 
(Gee, Karlsgodt, van Erp, Bearden, Lieberman & Belger, et al., 2012; Seiferth, Pauly, Habel, 
Kellermann, Shah & Ruhrmann, et al., 2008; Thompson, Papas, Bartholomeusz, Nelson, & 
Yung, 2013). The majority of studies do not report response times for emotion recognition 
stimuli. The reporting of reaction times can be a useful measure of processing speed 
(Salthouse, 1996). In a review paper, Salthouse (1996) proposes that a reduction in the speed 
in which many processing operations can be carried out then leads to impairments in 
cognitive tasks.  
IQ and level of functioning have also been implicated as important factors in relation to 
emotion processing in CHR and schizophrenia literature. Findings from the NAPLS-2 cohort 
(n=675 CHRs) have reported deficits in general emotion recognition with a specific deficit 
for the recognition for sad faces with small effect sizes. These were no longer significant 
after controlling of age and IQ (Barbato, Liu, Cadenhead, Cannon, Cornblatt, McGlashan & 
Woods, 2015). The authors argue that based on their results, IQ appears to have an impact 
on facial emotion recognition, however, due to the limited number of studies assessing the 
relationship between IQ and emotion recognition, a clear hypothesis could not be given. To 
the best of our knowledge, there are only another 2 studies which have looked at the 
relationship between IQ and emotion recognition, both with differing results. Thompson et 
al (2012) found no differences between CHR individuals and controls whilst Amminger et 
al (2011) found CHR participants to be impaired in the recognition of fear and sadness. A 
similar relationship between IQ and emotion recognition has been found in schizophrenia 
literature. Pomarol-Clotet et al. (2010) did not find any group differences in emotion specific 
recognition in a group of individuals with established schizophrenia. However, the clinical 
group were significantly slower at responding than controls. Importantly, the participants 
were matched on IQ. The authors argue that when steps are taken to reduce the effects of 
general intellectual impairment, there is no deficits in emotion recognition in schizophrenia. 
Considering our high functioning sample, this may help to explain our lack of findings of 
emotion recognition deficits. However, this claim cannot be substantiated due to the lack of 
IQ measurement.      
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Similarly, in a sample of individuals with a diagnosis of schizophrenia emotion recognition 
was not impaired in a high functioning group whilst emotion recognition deficits were 
present in a low functioning group (Karpouzian, Alden, Reilly & Smith, 2016). The authors 
argue that these findings suggest that emotion recognition deficits may be an important 
component of poor functioning, rather than a trait marker for schizophrenia.  
 
4.3 Cognition and Functioning  
 
Impairments in social and role functioning are key features of schizophrenia (Couture et al., 
2006; McGurk & Meltzer, 2000) and are related to the burden of psychotic disorders to 
patients, families, carers and the wider society (Jungbauer, Wittmund, Dietrich & 
Angermeyer, 2004; Knapp, Mangalore & Simon, 2004; Magaña, Ramírez García, 
Hernández & Cortez, 2007). There is now a robust body of evidence that these deficits are 
present in CHR-populations (Addington, Penn, Woods, Addington & Perkins, 2008b, 
Cornblatt, Auther, Niendam, Smith, Zinberg & Bearden et al, 2007; Velthorst, Nieman, 
Linszen, Becker, de Haan & Dingemans et al., 2010) and that neurocognitive functioning is 
related to functional deficits (Carrión, Goldberg, McLaughlin, Auther, Correll & Cornblatt, 
2011) and baseline-deficits predict functioning at follow-up (Lin, Wood, Nelson, Brewer, 
Spiliotacopoulos & Bruxner, et al., 2011; Lin, Yung, Nelson, Brewer, Riley & Simmons, et 
al., 2013).  
In the current study, we expected to find that the CHR-participants would display impaired 
global, social and role functioning at baseline. Moreover, based on previous findings 
(Carrión, Goldberg, McLaughlin, Auther, Correll & Cornblatt, 2011), we expected that 
processing speed is a predictor of poor functioning in CHR-participants. Our hypotheses 
were partially supported.   
 
4.3.1 Functioning in CHR-Participants 
 
The CHR and control groups did differ significantly on all three measures of functioning 
(GAF, GF Social and GF Role). The differences measured between groups on the three 
levels of premorbid adjustment (childhood, early and late adolescence) and the three 
measures of functioning all show large effect sizes. GAF measures current psychosocial 
60 
 
functioning along with symptom prevalence whilst GF social and GF Role measure 
functioning in each specific domain independent each other and of symptoms.  
CHR-participants in the current study had a mean GAF score of 60.36 which is higher than 
what is typically observed in CHR-literature (Ruhrmann, Schultze-Lutter, Salokangas, 
Heinimaa, Linszen Dingemans & Morrison, 2010). Results from the prospective European 
prediction of psychosis study (Ruhrmann, Schultze-Lutter, Salokangas, Heinimaa, Linszen 
Dingemans & Morrison, 2010) covered clinical characteristics of CHR-populations reported 
the mean of 245 at-risk participants (UHR and COGDIS) to be 51.1. Moreover, reduced 
GAF-scores may also relate to transitioning to psychosis (Velthorst, Nieman, Becker, van 
de Fliert, Dingemans, Klaassen, et al., 2009). For those CHR-individuals who do not convert, 
there is evidence that functioning may improve over time (Addington, Cornblatt, Cadenhead, 
Cannon, McGlashan & Perkins, et al., 2011). 
The CHR group in our sample demonstrated significant impairments in social and role 
functioning. Carrión et al. (2011) reported in a sample of clinically-referred CHR-
participants lower group social (5.94) and role (5.46) functioning. However, it is important 
to note that their sample were also younger as age may be an important factor for functioning. 
Similar findings were also reported by, Karlsgodt, Niendam, Bearden & Cannon (2009). 
However, Pelletier et al. (2013) measured non-clinical psychosis (NCP) in a group of 
individuals and those where found to have high-NCP (those who scored highest in NCP) 
reported functioning scores which were higher than our CHR group; social (8) and role (7.9). 
Similar to our sample, the participants in the latter study were university students. Our 
sample was predominantly students (university and college) as well as recruited through 
clinical services.  
Analysis of functioning between differing CHR-criteria revealed no significant differences 
for social and role functioning. Baseline GAF scores were significantly different between 
groups with the CAARMS+SPI-A group having poorer functioning relative to the CAARMS 
group and the SPI-A group. There were no significant differences between the CAARMS 
group and the SPI-A group. One explanation for the null findings for social and role 
functioning and the significant findings for GAF is that these are due to symptom severity 
rather than functional impairment. GAF measures a mixture of symptom severity, social and 
role functioning.  
Basic symptoms reflect the early stages of the prodrome (Schultze-Lutter, Addington, 
Ruhrmann & Klosterkötter, 2007) whilst CAARMS captures experiences in the later stages 
(Yung et al, 2006). Thus, individuals meeting only basic symptom criteria will be less 
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symptomatic than individuals who meet CAARMS criteria. A combination of CAARMS 
and SPI-A has been found to be associated with poorer outcomes and are the most effective 
at predicting transition to psychosis (Ruhrmann, Schultze-Lutter, Salokangas, Heinimaa, 
Linszen & Dingemans, et al., 2010). This is reflected in our findings with the SPI-A 
subgroup having the highest GAF scores followed by the CAARMS subgroup and finally 
CAARMS+SPI-A. Moreover, findings from a recent meta-analysis found that lower baseline 
global functioning predicted later transition to psychosis (Fusar-Poli, Rocchetti, Sardella, 
Avila, Brandizzi & Caverzasi, et al., 2015). Taken together these findings suggest that 
functional impairments may be important treatment targets for early intervention. 
Furthermore, CHR-individuals who were recruited from clinical services were more severely 
impaired in role functioning, and a statistical trend was observed for social functioning. GAF 
scores did not differ significantly between these groups. This suggests a potential difference 
between in CHR-individuals who are currently accessing clinical care. However, these 
results should be interpreted with caution. Individuals who were not recruited from clinical 
services may have had previous or current clinical care.   
These findings are similar to Mills et al. (2017) who compared individuals who met UHR 
criteria from a community sample to UHR-individuals recruited from clinical services. The 
community UHR-participants had less severe positive and negative symptoms and less 
severe general psychopathology. They had higher levels of social and role functioning 
relative to the UHR-participants from clinical services but lower levels of social and role 
functioning relative to healthy controls (Mills, Fusar‐Poli, Morgan, Azis & McGuire, 2017). 
The community UHR-participants were similar to UHR-participants from clinical services 
in age, ethnicity, gender, employment status, years of education, cannabis use and history of 
childhood trauma. The community UHR-participants were more likely to be first generation 
migrants.   
 
Moreover, Mills et al. (2017) from a general population sample found that those who met 
UHR criteria were much more likely to have reported an unmet need for clinical care when 
compared to those who did not. Approximately half of the community UHR-participants had 
sought help for psychological or emotional problem in the 12-months prior to assessment. 
The authors argue that this highlights a substantial number of individuals in the general 
population who meet UHR criteria but are not being seen by clinical services. However, it 
is important to be aware that UHR-individuals who were not referred through clinical 
services were not necessarily non-help seeking. Half of these individuals had already sought 
help, although, not always from specialised services. 
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4.3.2 Neurocognition as predictors of functioning  
 
Literature on the association of neurocognition and functioning in CHR-populations is 
sparse. Carrión et al. (2011) found that processing speed predicted both social and role 
functioning at baseline. Global neurocognitive performance was also found to predict both 
social and role functioning. Niendam et al. (2006) found levels of social functioning to be 
predicted by measures of verbal learning and memory as well as negative symptoms. Our 
results support the findings of Carrión et al. (2011) in relation to global neurocognitive 
performance being predictive of role functioning at baseline. However, our results do not 
support the findings that processing speed is an important factor for both social and role 
functioning in CHR as well as the relationship between social functioning and verbal 
learning.  
However, our findings do partially support data from the NAPLS-2 cohort. They found 
composite neurocognition was associated with both social and role functioning at baseline. 
Composite neurocognition at baseline was associated with role functioning, but not social 
functioning, at 12-month follow up (Meyer, Carrión, Cornblatt, Addington, Cadenhead & 
Cannon, et al., 2014).  
Our regression analysis found emotion recognition RT to be a significant predictor of GAF 
scores and social functioning at baseline. In addition, the BACS global score was a 
significant predictor of role functioning. However, these predictors explained only 7%, 9% 
and 9% of the data respectively. These findings support existing evidence that functional 
impairments and their relationship to neurocognition exist before the onset of psychosis and 
are not outcomes of chronic illness (Carrión, Goldberg, McLaughlin, Auther, Correll & 
Cornblatt, 2011; Niendam, Bearden, Johnson, McKinley, Loewy, & O'Brien et al., 2006). 
Functional impairment is also an important factor for CHR-groups regardless of transition 
to psychosis (Ruhrmann, Schultze-Lutter, Salokangas, Heinimaa, Linszen & Dingemans, et 
al., 2010; Addington, Cornblatt, Cadenhead, Cannon, McGlashan & Perkins, et al., 2011). 
Our findings extend this to highlight that such functional impairments are evident in a high-
functioning sample of CHR-participants. 
The variance in the data for our regression models are low. This is similar to other studies 
investigating neurocognitive predictors of functioning. Carrión et al. (2011) found that 
processing speed predicted both social and role functioning at baseline explaining 10% of 
variance for social functioning and 7% of variance for role functioning. Global 
neurocognitive performance was also found to predict both social and role functioning 
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explaining 8% and 5% of variance in the data respectively. The most likely explanation for 
this is that there are additional factors which could help explain poorer functioning in CHR 
samples, such as stigma and lack of social support. Negative symptoms have also been found 
to be an important factor in functional outcomes in CHR-participants (Niendam, Bearden, 
Johnson, McKinley, Loewy, & O'Brien et al., 2006) and in schizophrenia (Rabinowitz, 
Levine, Garibaldi, Bugarski-Kirola, Berardo & Kapur, 2012). Meyer et al. (2014) found 
negative symptoms to account for most of the variance in their data followed by composite 
neurocognition. Moreover, negative symptoms were the strongest predictors of social and 
role functioning at baseline and 12-month follow up with small to medium effects. This was 
followed by composite neurocognition which had small independent effects. Negative 
symptoms were also found to mediate the relationship between neurocognition and social 
and role functioning (Meyer, Carrión, Cornblatt, Addington, Cadenhead & Cannon, et al., 
2014). 
 
4.3.2 Social Cognition as predictors of functioning  
 
In an exploratory analysis, we investigated the relationship between emotion specific 
recognition and functional parameters. We included only RTs to specific emotional 
categories as predictors in the analyses. To the best of our knowledge, this is the first study 
to investigate emotion specific recognition and functional outcomes in a CHR-population. 
We found RTs to sad faces to be a significant predictor of GAF as well as RTs to fearful 
stimuli being a significant predictor of both social functioning and role functioning. These 
predictors explained 10% of the variance for each parameter of functioning.  
Pelletier et al. (2013) investigated emotion specific recognition in relation to social and role 
functioning in a group of students with non-clinical psychosis. They found associations 
between recognition of fear and social functioning in those who scored highest for NCP. 
Moreover, both social and role functioning were associated with general emotion 
recognition. These findings, together with the findings of the current study, suggest that 
emotion recognition may play a role in social and role functioning more specifically that fear 
plays a role in predicting social and role functioning. These findings are preliminary and 
existing literature is limited, therefore further research is needed to assess the relationship 
between specific emotion recognition categories and functional parameters. 
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4.4 General  
 
It is important to note the difference in our sample in relation to existing literature. The 
majority of at-risk studies recruit participants who are help seeking and are already within 
clinical services (Fusar-Poli, Carpenter, Woods & McGlashan, 2014) as well as often 
including a 30% drop in functioning (Yung, Phillips, Yuen & McGorry, 2004). These criteria 
were not inclusion criteria for this study and, as a result, the current sample in generally 
higher functioning than previous CHR-cohorts which can potentially account for some 
differences in the findings reported. 
Consistent with the current findings, previous CHR-studies have reported deficits in only 
some domains of neurocognition (Wood, Pantelis, Proffitt, Phillips, Stuart & Buchanan, et 
al., 2003; Kelleher, Murtagh, Clarke, Murphy, Rawdon & Cannon, 2013). However, these 
studies typically have small sample sizes with the possibility of being statistically 
underpowered which leads an increased the possibility of Type II errors. Studies involving 
large sample sizes have more consistently found deficits in all areas of neurocognition 
(Carrión, Goldberg, McLaughlin, Auther, Correll & Cornblatt, 2011; Seidman, Shapiro, 
Stone, Woodberry, Ronzio, Cornblatt, et al., 2016) as have meta-analyses (Bora & Murray, 
2014; Fusar Poli et al., 2012). Although, this is not the case for emotion recognition where 
conflicting findings have been reported even in large scale studies (Barbato, Liu, Cadenhead, 
Cannon, Cornblatt, McGlashan & Woods, 2015). Our lack of findings in some 
neurocognitive domains may be partly due to a statistical power issue, particularly for the 
Penn CNB tasks which had a small control group (n = 26). 
Multiple comparisons were performed when assessing between group differences in 
neurocognitive and social-cognitive domains which may have led to inflated error rates and 
the probability of making at least one Type I error. Conservative post hoc tests, such as 
Bonferroni, would lead to a lack in statistical power and a high probability of a Type II error. 
More liberal post hoc tests typically become unreliable when sample sizes are different. 
Given the sample size and differences in group sizes, post hoc tests were not performed. 
Thus, the reported differences between groups in neuro- and social cognitive factors should 
be interpreted with caution.        
These findings are the first to show neuro- and social cognitive and functional impairments 
in a predominantly high functioning group of CHR-individuals. A relationship between 
neurocognition, emotion recognition RTs and functional parameters was observed. These 
findings highlight possible treatment targets for CHR-individuals. This is important as CHR 
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status has been associated with significant distress, symptomology and functional 
impairment (Fusar-Poli, Carpenter, Woods & McGlashan, 2014). 
We investigated clinical characteristics between CHR-participants meeting differing CHR-
criteria as well as differences between those recruited via clinical services and those who 
were not. Investigation of individuals meeting differing CHR-criteria is important because 
these represent different stages of CHR progression and are associated with different 
outcomes and transition rates (Ruhrmann, Schultze-Lutter, Salokangas, Heinimaa, Linszen 
& Dingemans, et al., 2010). The CHR group which is the most predictive of transition to 
psychosis is a combination of basic symptoms plus CHR status (Fusar-Poli et al., 2013). This 
gives insight as to what may be the most meaningful treatment targets for early intervention. 
We found the CAARMS+SPI-A group to have significantly poorer global functioning 
relative to the other CHR-criteria suggesting this as a putative treatment target. 
Investigation into CHR-participants who are not necessarily recruited through clinical 
services is important because this can also help to identify important treatment targets for 
early intervention. Our findings suggest both social and role functioning along with cognitive 
deficits as possible treatment targets for early intervention.   
Follow up analysis will offer insights into transition rates for this sample of CHR-
participants.           
 
4.6 Conclusions 
 
This thesis has highlighted that neuro- cognitive and social cognitive deficits are present in 
a high functioning sample of individuals who are CHR for psychosis. Global functioning is 
poorer in those who meet combined basic symptom and CHR criteria. Role functioning, 
global cognition and to a lesser extent social functioning are poorer in individuals recruited 
through clinical services. These highlight putative treatment targets for early intervention. 
Emotion recognition RTs are associated with GAF and social functioning whilst global 
cognition is associated with role functioning. More specifically, RTs for sad faces are 
associated with GAF whilst RTs for fearful faces are associated with social and role 
functioning. However, these factors only explain a small amount of variance in the data. 
Future research should focus on emotion specific recognition include other factors, such as 
negative symptoms, to improve predictive models and highlight further treatment targets.     
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